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 The aim of this thesis project was to investigate the use of a recombinant adeno-
associated virus (rAAV) as a gene therapy vector to target both the anabolic and catabolic 
axes of cartilage homeostasis in order to enhance cartilage repair capabilities and prevent joint 
degradation.  The specific aims of the research were to 1) evaluate healing of full-thickness 
chondral defects in femoral trochlear ridges repaired with autologous chondrocytes 
transduced ex vivo with an rAAV5 vector overexpressing the anabolic protein, insulin-like 
growth factor I (IGF-I); 2) investigate the impact of post-transcriptional silencing of 
interleukin-1β (IL-1β) mediated by rAAV2 expressing a short hairpin IL-1β silencing motif in 
chondrocytes cultured in an osteoarthritic model and; 3) elucidate the humoral and cell-
mediated immune response, and its impact on transgene expression, following direct intra-
articular (IA) injection of rAAV2 and rAAV5 overexpressing IGF-I.  
  
Autologous chondrocytes transduced ex vivo with rAAV5-IGF-I were arthroscopically 
implanted, in a fibrin vehicle, into 15mm diameter full-thickness chondral defects created in 
the lateral trochlear ridges of horses.  Transgene expression was assessed by serially 
quantifying IGF-I concentration in the synovial fluid.  Defect healing was assessed 
arthroscopically at 8 weeks post-implantation.  Long-term healing at 8 months post-
 implantation was assessed using gross, histological, immunohistochemical, and biochemical 
parameters.  rAAV5-IGF-I treated defects had improved short and long-term healing with 
improved tissue architecture and collagen type II content compared to defects repaired with 
naïve chondrocytes.   
  
Transduction of chondrocytes with rAAV2 expressing a short hairpin IL-1β led to 
significantly reduced IL-1β mRNA expression following stimulation with lipopolysaccharide 
(LPS).  Down-regulation of additional key catabolic cytokines and degradative enzymes, 
including tumor necrosis factor (TNF)-α and a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS)-5, was also seen in transduced cultures.  Post-
transcriptional silencing of IL-1β appeared to limit the catabolic cascade seen in cartilage 
following LPS simulation. 
 
 Direct intra-articular injection of rAAV2- and rAAV5-IGF-I led to prolonged 
transgene expression without any significant local joint inflammation.  Carpal joints injected 
with rAAV5-IGF-I had significantly higher levels of IGF-I in the synovial fluid compared to 
rAAV2-IGF-I despite a more robust and diverse humoral immune response to AAV5.  A cell-
mediated immune response was not noted in either treatment group.    
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Overall Goal of Dissertation Research 
 
The overall goal of this thesis project was to investigate the impact of dual-axis gene 
therapy in promoting cartilage repair and preventing osteoarthritis (OA), using an adeno-
associated virus (AAV) as a viral vector.   In this dissertation research, the anabolic and 
catabolic axes of cartilage homeostasis were targeted; the effects of AAV-mediated growth 
factor overexpression and catabolic cytokine knockdown were investigated as potential 
methods of improving the repair capabilities, and limiting the degeneration, of articular 
cartilage.   These goals were met using both in vitro and in vivo experiments in the equine 
model.                                                                                                        
 
This introductory chapter provides pertinent background information and discussion of 
gene therapy for cartilage repair.  The first aim of this thesis is presented in chapter 2 in 
which, the long-term repair of large, full-thickness chondral defects filled with autologous 
chondrocytes transduced ex vivo with an AAV vector overexpressing insulin-like growth 
factor (IGF-I), is investigated.  IGF-I, a critical anabolic and mitogenic protein in chondrocyte 
homeostasis, was overexpressed in chondrocytes grafted into experimentally created defects 
in the lateral trochlear ridge of the femur of horses. 
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The second aim, presented in chapter 3, evaluates the effects of post-transcriptional 
silencing of IL-1β using an AAV vector expressing a short hairpin sequence targeting IL-1β.  
The benefit of upregulation of anabolic growth factors, such as IGF-I, is likely tempered by 
the known concurrent increase in catabolic factors following cartilage damage and during the 
subsequent degenerative process.  IL-1β is arguably the most important catabolic factor in the 
damaged and arthritic joint; it leads to breakdown of the extra-cellular matrix (ECM) and may 
seriously limit the reparative effects of IGF-I.  Knockdown of IL-1β was examined in vitro 
using chondrocyte monolayer and cartilage explant cultures. 
 
The beneficial effects of gene therapy in cartilage repair were clearly demonstrated in 
the first two aims; however, a humoral immune response was noted in horses exposed to the 
AAV5 vector following ex vivo transduction of chondrocytes.  Due to concerns regarding the 
effect of the humoral immune response on vector effectiveness, the final aim of this 
dissertation research evaluated the local and systemic humoral and cell-mediated immune 
response, and transduction efficiency, of two AAV serotypes injected directly intra-
articularly.  Understanding the immune response to AAV is vital in the development of AAV 
as a clinically relevant vector for gene therapy as the immune response may lead to limited 
transduction and transgene silencing.  
 
Overall conclusions of this research and future directions are presented together in the 
final chapter.   
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Anatomy of Articular Cartilage  
  
Articular cartilage is found covering bone in all diarthrodial (or movable) joints.  This 
specialized form of cartilage, referred to as hyaline cartilage, is composed mainly of water 
(75%), collagen type II (15%) and proteoglycans (10%).
1
  Chondrocytes, which make up only 
2% of hyaline cartilage, are the only cell type in cartilage and are solely responsible for 
production and maintenance of the ECM, an intricate network of woven collagen type II 
fibrils and proteoglycans.  Chondrocytes are isolated within lacunae and are surrounded by a 
pericellular matrix dense in decorin and aggrecan.   They communicate with each other, and 
their environment, through soluble mediators (e.g. growth factors, cytokines) and cell 
adhesion molecules.  Chondrocytes arise from mesenchymal progenitor cells, and following 
maturation their growth potential is minimal.   
 
The ECM produced by chondrocytes is a woven matrix of collagen, proteoglycans and 
other glycoproteins (e.g. fibronectin) (Figure 1.1).  The vast majority (90-95%) of collagen is 
collagen type II that forms homotrimer helices around collagen type XI fibrils.  Procollagen is 
secreted by chondrocytes and is cleaved into tropocollagens extracellularly by specialized 
proteases prior to formation of a triple helix.  Aggrecan composes 85% of the proteoglycans 
and consists of a core protein with covalently attached glycosaminoglycans (GAGs).  Keratan 
sulfate, chondroitin-6-sulfate and chondroitin-4-sulfate are the main GAGs in aggrecan.  The 
aggrecan monomer is bound to hyaluronan stabilized by link protein.    Other smaller  
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Figure 1.1 Diagram of the extra-cellular matrix (ECM) of articular cartilage including the 
collagen macrofibrillar network large aggregating proteoglycans (aggrecan) with hyaluronic 
acid. From Poole AR: Cartilage in Health and Disease. In Koopman W ed. Arthritis and 
Allied Conditions. A Textbook of Rheumatology. Ed 14. Vol 1. New York, Lippincott 
Williams & Wilkins pp 2260-2284, 2001.   
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proteoglycans such as decorin, fibromodulin and biglycan are found in lesser quantities within 
the ECM.   
 
Articular cartilage is organized into zones defined by the specific orientation of 
chondrocytes and collagen fibrils, and ratio of proteoglycans to collagen (Figure 1.2).
1
  The 
zonal organization of articular cartilage contributes to the biomechanical function of the 
tissue. The superficial (tangential) zone is defined by elongated cells and collagen fibrils that 
are oriented parallel to the surface.  Cellular density is highest in this zone with aggrecan 
content being lower compared to deeper zones.  The intermediate zone contains fewer cells 
that are more rounded, more collagen fibrils that are randomly arranged, and increased 
amounts of aggrecan.  Finally, the deep (radiate) zone is defined by cells organized into 
columns parallel to the longitudinal axis of the bone.  This zone has the highest aggrecan and 
lowest collagen content.  Below the deep zone lies the tidemark, which marks the junction of 
non-calcified and calcified cartilage.  The thin, but impenetrable, layer of calcified cartilage 
covers the subchondral bone.   
 
The ECM affords the impressive biomechanical properties of articular cartilage with 
collagen providing tensile strength and proteoglycans providing compressive stiffness.  
Hyaline cartilage is also supported by dense subchondral bone, which provides additional 
compressive strength to the joint.  The calcified cartilage layer prevents blood vessels in the 
subchondral bone from entering cartilage; therefore, articular cartilage is an avascular and  
6 
 
 
 
 
Figure 1.2 Diagram of articular cartilage depicting the zonal organization of cartilage 
including orientation of chondrocytes and collagen, and the relationship of cartilage to the 
subchondral bone. From Matta C and Zakany. Calcium signaling in chondrogenesis: 
implications for cartilage repair. Frontiers in Bioscience, Scholar. 5:305-324, 2013.
 7 
 
aneural tissue that depends on diffusion of nutrients from the synovial fluid.  Due to the 
avascular and hypoxic nature of cartilage, chondrocytes have low metabolic rates and limited 
proliferative capacity.  Remarkably, homeostasis of the ECM depends on the chondrocyte to 
balance synthesis, assembly, and degradation of matrix proteins.
1
 Disruption of the 
physiologic balance, as seen following trauma to the articular surface and during OA, leads to 
dysregulated degradation of the ECM and eventual loss of a functional surface.   
  
Joint Injury and Cartilage Repair 
 
Articular cartilage is capable of withstanding considerable force, however, excessive 
trauma and injury occurs frequently, especially during athletic activity.  The poor intrinsic 
healing capabilities of articular cartilage are due to its hypocellular, avascular and aneural 
nature.
2
  Chondrocytes do have a limited ability to proliferate and increase ECM synthesis 
following injury; however, restoration of the matrix only occurs if the rate of loss does not 
exceed chondrocyte-mediated synthesis.  Full-thickness cartilage lesions that are left untreated 
are filled with fibrocartilage that is biochemically and biomechanically inferior to hyaline 
cartilage.
3,4
  Fibrocartilage is deficient in proteoglycans and collagen type II while having an 
over-abundance of collagen type I when compared to hyaline cartilage.
5
  Due to the poor to 
minimal intrinsic healing capabilities of cartilage, joint injury often precipitates OA with 
eventual degeneration of the joint surface.
6
  Methods of improving cartilage repair following 
injury are vital to the prevention of this debilitating disease.  
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Current treatment modalities to improve cartilage repair include simple debridement, 
enhanced intrinsic repair through microfracture or subchondral drilling, osteochondral 
transplantation (mosaicplasty), autologous chondrocyte implantation (ACI) and matrix-
induced autologous chondrocyte implantation (MACI).  Techniques for enhancing intrinsic 
repair include microfracture and subchondral drilling, both of which penetrate the 
subchondral bone plate to allow migration of mesenchymal stem cells (MSCs) and growth 
factors from the bone marrow to facilitate healing.
7,8
 Although some benefit has been reported 
with these interventions, long-term outcomes have been disappointing due to apparent 
weakness of the repair tissue that forms.  Mosaicplasty,
9,10
ACI,
11,12
 and MACI
13
 are all cell-
based treatments in which defects are filled with autologous chondrocytes either grafted 
immediately from donor sites (osteochondral plugs), or harvested and expanded in the 
laboratory prior to grafting within a matrix (MACI) or beneath a periosteal flap (ACI).  These 
cell-based repair strategies have shown promise for longer-term repair both in equine and 
human patients.
14,15
  Production of a more hyaline-like repair tissue, versus fibrocartilage seen 
in non-cell based techniques, may explain improved treatment outcomes with these 
techniques.
15-17
  However, regeneration of native hyaline cartilage remains challenging and 
genetic manipulation of chondrocytes may further enhance repair.
18
  Chondrocytes can be 
successfully cultured in the laboratory allowing for ex vivo transduction.  In addition, the 
enclosed joint offers an ideal environment for in vivo transduction following direct intra-
articular injection of gene therapy vectors.
19
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Osteoarthritis  
 
Osteoarthritis, a degenerative and debilitating disease, is the most common form of 
arthritis with more than 27 million people affected in the USA
20
 and estimated annual health 
care costs exceeding $89 billion.
21
  Following injury, chondrocytes undergo a shift in the 
balance between anabolism and catabolism, with decreased production of anabolic factors 
necessary for maintenance of the ECM and concurrent increased production of degradative 
cytokines and enzymes.  Both acute joint injury and chronic OA are accompanied by an 
increase in the production of catabolic cytokines including interleukin-1β (IL-1β ) and tumor 
necrosis factor-α (TNF-α) produced by activated synoviocytes and chondrocytes,22 as well as 
an influx of inflammatory mediators produced by leukocytes entering the joint due to 
increased vascular permeability.  Increased production of catabolic cytokines and 
inflammatory mediators up-regulate destructive enzymes, including matrix metalloproteinase 
(MMP)-1, -3 and -13 and a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS)-4 and -5 (aggrecanases).
23
  More specifically, IL-1β has been shown to induce a 
cascade of pro-inflammatory mediators including MMPs and prostaglandin E2 (PGE2)
24,25
 
and causes proteoglycan degradation while inhibiting collagen type II synthesis.
26,27
  Overall, 
these alterations in the joint environment lead to disruption of cartilage homeostasis and 
progressive degradation of the ECM with potential for permanent damage to the articular 
cartilage surface.   
 
Clinical features of OA include pain, decreased range of motion, and joint effusion.  
Loss of cartilage, subchondral bone sclerosis, subchondral cysts, osteophytosis and synovitis 
 10 
 
are also common.   Currently, there are no effective disease-modifying osteoarthritis drugs to 
halt or reverse OA.  Therefore, therapeutic interventions that interfere with damaging 
catabolic cascades associated with cartilage degeneration and progression of OA would be of 
great benefit. 
 
Growth Factors 
 
The effects of several different growth factors on chondrocyte metabolism and 
cartilage repair have been investigated including insulin-like growth factor I (IGF-I),
28,29
 
transforming-growth factor β (TGF-β),30,31 and bone morphogenetic protein (BMP)-2 and 
7.
32,33
 Amongst these growth factors, IGF-I has been identified as the critical anabolic and 
mitogenic protein in cartilage, with notable autocrine and paracrine effects.
34
  Previous studies 
have shown that IGF-I increases aggrecan and collagen type II content in chondrocyte 
cultures, including explants, monolayer and three-dimensional systems as well as enhancing 
the repair potential of chondrocytes grafted into cartilage lesions in horses.
16,28
  Additionally, 
it has been suggested that IGF-I plays an important role in the healing of damaged cartilage as 
it partially protects, and aids in the recovery of, the ECM following experimentally induced 
damage with IL-I and TNF-α.29,35  Although chondrocyte grafts supplemented with exogenous 
IGF-I have been used in clinical practice,
14
 the transitory nature of growth factor 
supplementation has led to investigation of gene therapy approaches to allow for persistent 
transgene expression.    
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Catabolic Cytokines and Degradative Enzymes 
 
Interleukin-1β is a catabolic cytokine that is considered to be a primary instigator in 
the degradation of articular cartilage and development of OA.
36-38
   It is a potent catabolic 
regulator of chondrocytes and acts to decrease proteoglycan synthesis while increasing 
protease-induced proteoglycan degradation.
25
  More specifically, IL-1β directly down-
regulates expression of collagen type II, while up-regulating expression of collagen type I and 
III, and inhibits aggrecan synthesis by inhibiting core protein expression.
38,39
  Expression and 
secretion of destructive MMPs is also concurrently upregulated.
40
  Additionally, IL-1β has 
general pro-inflammatory effects with increased expression of inflammatory mediators such 
as prostaglandin E2 (PGE2)
41
 and nitric oxide (NO),
42
 and is likely involved with the pain 
mechanisms in OA joints.
43
 
 
Proteolytic enzymes that target the macromolecules of the ECM play an important role 
in cartilage destruction.  Both MMPs and aggrecanases (ADAMTS) are up-regulated 
following cartilage injury and during the arthritic process. MMP-1 (collagenase 1), MMP-3 
(stromelysin 1) and MMP-13 (collagenase 3) are key players, with MMP-13 being identified 
as the major collagenase in the OA joint.
44
  MMP-13 cleaves collagen type II, aggrecan and 
fibromodulin.  In addition the cleaved fragments of collagen type II induce more expression 
of MMP-13 leading to a vicious cycle of destruction.  The ADAMTS family of proteases also 
contributes to degradation of cartilage in OA by targeting and cleaving aggrecan.
45
  There is 
evidence to suggest that aggrecanase mediated degradation by ADAMTS-4 and ADAMTS-5 
is the predominant cause of ECM breakdown.
46
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Therapies directed towards decreasing cytokine production in the joint have been used 
successfully in rheumatoid arthritis.
47
  Interleukin-1 receptor antagonist (IL-1RA) 
competitively binds the IL-1 receptor and has been shown to decrease the degradative effects 
of IL-1.
48
  IL-1Ra therapy has been used to treat OA.  However, results have been 
disappointing likely because the beneficial effect of IL-1Ra decreases rapidly as continued 
endogenous production of IL-1 alters the equilibrium to favor IL-1/IL-1R binding and re-
activation.
49
  Post-transcriptional silencing of IL-1β mediated by RNA interference strategies 
could offer a superior, more sustainable method of cytokine control. 
 
RNA Interference Strategies 
 
RNA interference (RNAi) was originally described in Caenorhabditis elegans by Fire 
and Mello.
50
  It is a highly conserved, biologic process in eukaryotes that involves sequence-
specific post-transcriptional gene silencing.  mRNAs are specifically targeted by short (19-21) 
complementary RNA sequences that mark the transcript for degradation or prevent 
translation.  Small RNA sequences can be endogenously produced, such as microRNA 
(miRNA), or exogenously introduced into the cell in the case of small interfering RNA 
(siRNA) or short hairpin RNA (shRNA).  Regardless of the source, small double-stranded 
RNA (dsRNA) is cleaved by the endoribonuclease Dicer and then incorporated into the RNA-
induced silencing complex (RISC).  The RNA strands are separated by RISC and then the 
guide strand is shuttled to complementary mRNA.  Following binding of the guide strand, 
complementary mRNA is degraded or translation is inhibited by preventing appropriate 
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ribosomal binding.
51,52
   
 
The RNAi pathway is an innate cellular process that plays a large role in the regulation 
of gene expression, preservation of heterochromatin and maintenance of genomic stability by 
limiting expression of transposons.
53-55
  However, the RNAi pathway can also be exploited in 
biological systems by specifically targeting genes to knockdown.  siRNAs were originally 
used to achieve silencing effects.  However, these molecules can be difficult to introduce into 
cells, have transient effects due to intracellular degradation and can elicit an innate immune 
response.
56
  Alternatively, shRNA can be expressed by non-viral or viral vectors, allowing for 
increased transduction efficiency and sustained knockdown effects.
57
   
 
Gene Therapy for Cartilage Repair 
  
Gene therapy approaches to enhance cartilage repair and treat OA have great potential, 
as vectors carrying transgenes can be injected intra-articularly for concentrated, local 
therapeutic protein production.  Gene therapy techniques, which provide long-term in situ 
expression of repair-enhancing genes, would be superior to repeated injections or depots of 
peptide that are transient.  Additionally, injection of vectors into the discrete articular 
environment may avoid some of the potential systemic effects of intravascular administration.  
Both ex vivo and in vivo strategies have been investigated, i.e. implantation of transduced cells 
into the joint vs. direct intra-articular injection of gene therapy vectors.  Gene transfer in the 
articular environment was first reported as a therapy for rheumatoid arthritis in which a 
retrovirus was successfully used to express IL-1Ra in human joints.
58
  Although these studies 
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demonstrated proof-of-concept, significant safety concerns surrounded retroviral vectors due 
to genomic integration.
59
  Other viral vectors investigated for use in OA have included 
lentiviral
60
 and adenoviral
61
 vectors due to high transduction efficiency both in vitro and in 
vivo.   Although adenovirus has high transduction efficiency it is comparatively 
immunogenic, inciting significant inflammatory responses and has been associated with 
serious medical side effects in humans including fatalities.
62
  AAV may be a more feasible 
and clinically relevant vector for gene therapy as it lacks pathogenicity, can invade dividing 
and non-dividing cells, has long-term transgene expression in animal models, and appears to 
be minimally immunogenic.
63
   
 
Adeno-associated Virus 
 
AAV is a small (20-25nm), non-enveloped, single-stranded DNA virus in the family 
Parvoviridae, genus Dependovirus.
63
  AAV depends on a helper virus, usually adenovirus or 
herpesvirus, for effective replication.  Wild type AAV2 (wtAAV2) is capable of site-specific 
integration (human chromosome 19q13.4).  However, recombinant AAVs are not capable of 
productive infections, very rarely capable of genomic integration, and persist in the cell as 
concatemers, allowing for long-term transgene expression.  At present there are 12 known 
AAV serotypes isolated from humans with more than 100 serotypes isolated from non-human 
primates.
63
  The wild-type genome is ~5kb with 2 open reading frames: rep and cap.  The rep 
gene codes 4 different replication proteins (Rep78, Rep68, Rep52, Rep40) through alternate 
splicing.  The cap gene codes 3 viral proteins (VP1, VP2, VP3) that form the viral capsid.  
The 2 genes are flanked by inverted terminal repeats that assume a T-shaped hairpin structure.  
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The ITRs are the only genomic sequences required in cis for replication and packaging of 
AAV.   
 
AAV, being a single-stranded DNA virus, requires second strand synthesis of the viral 
genome prior to transcription and expression of transgenes.  More recently a self-
complementary AAV has been developed to decrease the lag time between transduction and 
transgene expression.  scAAV contains a dimeric inverted repeat that can fold into dsDNA 
without the need for second strand synthesis.
64
  scAAV vectors appear to have both enhanced 
transduction efficiency and onset of gene expression.
65
 
 
Recombinant AAV vectors for experimental and clinical use are generally prepared 
using a triple-plasmid transfection system in which 3 different plasmids are used to transfect 
HEK 293 cells.
66
  The first plasmid, an adenovirus helper plasmid, supplies necessary Ad 
proteins (E1A, E1B, E4, E2A) for the helper function. The second plasmid, an AAV helper 
plasmid, supplies the rep and cap genes required for capsid production and viral packaging.  
The third plasmid, an AAV transfer plasmid, contains the transgene of interest between 2 
inverted terminal repeats.   
 
AAV has been used successfully in many preclinical studies in mice, rabbits, dogs and 
non-human primates and is now being used widely in clinical gene therapy trials for several 
diseases including hemophilia B,
67
 Leber’s congenital amaurosis,68,69 and limb-girdle 
muscular dystrophy.
70
  Tissue tropism has been shown for several AAV serotypes and these 
affinities are likely species-specific.  AAV5 has been shown to provide efficient transgene 
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expression in equine chondrocytes in vitro.  Other serotypes, including AAV2, have been 
evaluated for transduction efficiency of articular cells; however, preliminary data in our 
laboratory comparing rAAV2 and rAAV5 revealed optimal transduction of chondrocytes by 
AAV5 at a dose of 10
5
vg/cell.
71
   
 
Immune Response to AAV 
  
Originally thought to be minimally immunogenic, concerns regarding the innate and 
adaptive immune response to AAV have become more prominent as these vectors have 
expanded into clinical use.  At this time, the innate response to AAV vectors appears low, 
especially compared to adenoviral vectors,
72
 and seems to be mediated primarily through toll-
like receptor (TLR) 9 signaling.
73
  TLR9 may recognize viral genomes following uncoating in 
the cytoplasm, subsequently inducing pro-inflammatory cytokines and type I interferons 
(IFNs).  The humoral response appears to be quite prevalent with an estimated 20-40% of 
humans having neutralizing antibody (NAb) titers > 1/20 against any given serotype.
74,75
  
Prevalence of NAbs depends on serotype; approximately 80% of humans have NAbs against 
AAV2.
74
  Several animal and human clinical studies have shown that titers as low as 1:2 – 1:4 
can prevent successful transduction and transgene expression.
67,76,77
  In order for a humoral 
immune response to occur, B cells must recognize the viral capsid via membrane-bound 
immunoglobulins (B cell receptor), followed by internalization, processing and presentation 
by MHC II.  Activated B cells can then either undergo clonal expansion and differentiation 
into antibody-secreting plasma cells or form germinal centers in the lymph nodes where 
memory B cells are formed.
78
  In comparison to a seemingly consistent humoral response, 
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cell-mediated responses to AAV vectors appear to be less common.  
 
A lack of significant CD4+ T cell responses may be because rAAVs do not readily 
transduce antigen-presenting cells (APCs).
79,80
  Additionally, the weak activation of innate 
immunity by AAV limits the stimulation of maturation of APCs.  Activated APCs are able to 
upregulate expression of MHC II and co-stimulatory molecules CD80/86 and CD40, as well 
as release pro-inflammatory cytokines and chemokines, thereby enhancing their ability to 
process and present antigen.
72
  CD8
+
 T cell responses to AAV have been shown in animal 
models and humans.
81,82
  It is hypothesized that, following transduction and viral uncoating, 
some capsid remains in the cytosol and is processed by the proteasome prior to presentation 
on MHC I molecules.  AAV capsid presentation by MHC I results in activation and expansion 
of capsid-specific CD8
+
 memory T cells with subsequent removal of transduced cells.  Cross-
presentation by APCs is also possible with exogenous antigen taken up, processed and 
presented by MHC I to CD8
+
 T cells instead of the normal MHC II pathway for such 
exogenous antigen.   
 
Understanding the immune response to AAV is vital to its success as a gene therapy 
vector as the innate, humoral and cell-mediated immune response play major roles in vector 
effectiveness and host tolerance of AAV-mediated treatment modalities. 
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Conclusion 
 
Trauma to the articular surface can precipitate irreversible loss of chondrocyte 
function and degradation of the ECM leading to OA.  End-stage treatment for osteoarthritic 
joints in man is total joint replacement which can alleviate pain but is costly, often needs 
repeating, and does not offer return to full function.  It is widely accepted that preventing the 
development of OA following articular cartilage injury would be much more efficient and 
useful.  Quelling of the catabolic cascade and promotion of anabolism following injury may 
return physiologic balance to the cartilage and prevent development of OA and eventual loss 
of function.  Gene therapy for cartilage repair targeting both axes of cartilage homeostasis is a 
promising avenue to achieve this goal. 
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CHAPTER 2 
 
 
IMPLANTATION OF rAAV5-IGF-I TRANSDUCED AUTOLOGOUS CHONDROCYTES 
IMPROVES CARTILAGE REPAIR IN FULL-THICKNESS DEFECTS IN THE EQUINE 
MODEL 
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Abstract 
 
Cartilage injury often precipitates debilitating osteoarthritis due to poor healing 
capabilities. Autologous chondrocytes transduced with rAAV5-IGF-I were evaluated in 
chondral defects in a large animal model of cartilage repair. Cartilage was harvested from the 
talus of 24 horses; chondrocytes were isolated and stored frozen.  Twenty million cells were 
cultured and transduced with 10
5
 AAV vg/cell 48 hours prior to implantation. Chondrocytes 
from 8 horses were transduced with rAAV5-IGF-I, chondrocytes from 8 horses with rAAV5-
GFP, and chondrocytes from 8 horses were not transduced. A 15mm full-thickness chondral 
defect was created arthroscopically in the lateral trochlear ridge of the femur in both 
femoropatellar joints.  The treatment defect was filled with chondrocytes in fibrin.  Control 
defects in the opposite limb received fibrin alone.  rAAV5-IGF-I transduced chondrocytes 
resulted in significantly better healing scores at 8 week arthroscopy and 8 month necropsy 
when compared to the fibrin control.  At 8 months, rAAV5-IGF-I defects had better 
histological scores than control and defects repaired with naïve chondrocytes.  rAAV5-IGF-I 
defects had increased chondrocyte predominance and increased collagen type II, all features 
of hyaline-like repair tissue. The equine model closely approximates human cartilage healing; 
indicating AAV-mediated genetic modification of chondrocytes may be clinically beneficial 
to human patients.   
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Introduction 
 
Damaged articular cartilage often precipitates painful and debilitating osteoarthritis 
(OA).
1
  Joint injury and OA are often career-ending in athletes and are one of the most 
common causes of disability in the aging population.  Cartilage has minimal to no intrinsic 
healing capabilities,
2
 prompting investigation of varied methods to improve repair.  Full-
thickness lesions that are left untreated fill with fibrous tissue which is biochemically and 
biomechanically inferior to hyaline cartilage.
3
  Techniques to improve cartilage repair have 
been investigated including marrow stimulation,
4
 osteochondral transplantation 
(mosaicplasty),
5
 and more recently autologous chondrocyte implantation (ACI).
6
  Cell-based 
cartilage repair has shown promising long-term results in equine and human patients with 
production of hyaline-like repair tissue following transplantation of chondrocytes into 
chondral defects.
7
  However, repair tissue may be further improved through the genetic 
manipulation of the donor chondrocytes.   
 
Previous chondrocyte transplantation studies in the equine model have used allogeneic 
chondrocytes from juvenile donors
8
 as these cells are easily accessible from donor animals, 
limit treatment to one surgical event and decrease donor site morbidity.  However, the 
potential detrimental effect of the host immune response on healing continues to be of 
concern.  Although chondrocytes are generally considered to be immunoprivileged when 
contained in the extra-cellular matrix (ECM),
9
 they express MHC I and II
10
 and could incite 
an immune response.  Use of autologous chondrocytes eliminates potential immune responses 
to cells, which could benefit overall repair.    
 30 
 
Insulin-like growth factor-I (IGF-I) has been identified as a critical anabolic and 
mitogenic protein in chondrocyte metabolism and cartilage repair.
11
  IGF-I increases aggrecan 
and collagen type II content in chondrocyte cultures, including explants, monolayer and three-
dimensional systems, as well as enhancing the repair potential of chondrocytes grafted into 
cartilage lesions in horses.
12,13
  Additionally, it has been suggested that IGF-I plays a role in 
the healing of damaged cartilage as it partially protects and aids in the recovery of the ECM 
following experimentally induced damage with IL-I and TNF-α.14,15  Although chondrocytes 
supplemented with exogenous IGF-I have been used in clinical practice,
16
  the transitory 
nature of growth factor supplementation has led to investigation of gene therapy approaches. 
 
Viral vectors including adenovirus and retrovirus have been examined for 
musculoskeletal gene therapy due to high transduction efficiencies but concerns regarding 
immunogenicity and genome integration have limited their use.  Adeno-associated virus 
(AAV) may be a more feasible and clinically relevant vector as it lacks pathogenicity, can 
transduce dividing and non-dividing cells, has long-term transgene expression, and transduced 
cells appear to be minimally immunogenic.
17
  Recombinant AAVs are not capable of 
productive infections and rarely integrate into host genomes.  AAV, being a single-stranded 
DNA virus, requires second strand synthesis of the viral genome prior to transcription and 
expression of transgenes.  More recently a self-complementary AAV (scAAV) has been 
developed to decrease the lag time between transduction and transgene expression as the 
genome can fold into dsDNA without the need for second strand synthesis.
18
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The objective of this study was to evaluate short- and long-term cartilage healing in 
full-thickness chondral defects repaired with autologous chondrocytes transduced ex vivo with 
a rAAV5 vector overexpressing IGF-I.  We hypothesized that autologous chondrocytes 
overexpressing IGF-I would improve articular cartilage healing as measured by morphologic, 
histologic and biochemical parameters.   
 
Materials and Methods 
 
Adeno-associated vectors 
 
Equine IGF-I cDNA was originally derived from RNA isolated from liver and 
cartilage from a 2 year old Thoroughbred horse.  Three overlapping clones using primers 
derived from known sequence data for equine IGF-I (GenBank accession number U28070) 
were used to amplify the sequence.  Full-length equine IGF-I cDNA and GFP were each 
subcloned into the rAAV transfer plasmid pHpa-trs-SK using SacII and Not sites.  The 
transgenes were flanked by inverted terminal repeats and under control of the CMV promoter.  
scAAV5-IGF-I and scAAV5-GFP vectors were generated by the Research Vector Core at The 
Children’s Hospital of Philadelphia (CHOP) in HEK293 cells using the triple plasmid 
transfection method in which cells were transfected with three different plasmids. The 
plasmids included: 1) rAAV-IGF-I or rAAV-GFP construct, 2) the AAV rep and cap genes 
and 3) the adenovirus helpervirus.  
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Cartilage biopsy and graft preparation 
 
Twenty-four horses (11 geldings, 13 mares), between two and four years old (mean 
2.9 years) and free of hindlimb musculoskeletal disease underwent cartilage biopsy using a 
protocol approved by the Institutional Animal Care and Use Committee.  There were 13 
Thoroughbreds, 6 Quarter Horses, and 5 American Paint Horses, with a mean (± SEM) weight 
of 460.2 (± 15.8) kg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
Horses were anesthetized and articular cartilage (2-3 g) was arthroscopically harvested 
from the non-weight bearing portions of the distal medial and lateral trochlear ridges of one 
randomly selected talus.  Chondrocytes were isolated, expanded under monolayer culture 
conditions to 20 x 10
6
 cells and then kept frozen in liquid nitrogen as previously described.
19
   
Chondrocytes were prepared for surgical implantation as previously described,
20
 however, 
cells were transduced 48 hours prior to surgery in Opti-Mem (Invitrogen, Grand Island, NY) 
with rAAV5-IGF-I (n=8), rAAV5-GFP (n=8), or no virus as a negative control (n=8) at a 
dose of 10
5 
vg/cell for 2 hours.  Following transduction, chondrocytes were suspended in 
cryoprecipitated autogenous fibrinogen that was prepared from previously collected plasma.
21
   
 
Chondrocyte implantation 
 
Horses were anesthetized, synovial fluid was collected from both femoropatellar joints 
and bilateral arthroscopy was performed.  A full-thickness chondral defect that extended 
down to, but not through, the subchondral plate, was created on the lateral trochlear ridge of 
 33 
 
both femurs using a 15mm diameter fluted spade-bit cutter with a sharpened perimeter skirt 
(Special Devices, Grass Valley, CA) under arthroscopic guidance.  Residual cartilage and 
calcified cartilage were removed using a loop curette.  Each horse served as its own control 
with one defect being grafted with chondrocyte/fibrinogen mixture and the contralateral 
defect grafted with fibrin alone.  Chondrocyte implantation was performed using helium gas 
for joint distension.  A double-barreled syringe containing the fibrinogen/chondrocyte mixture 
in one syringe and calcium-activated bovine thrombin (500U/ml, Sigma, St Louis, MO) in the 
other syringe to polyermize the fibrinogen was used, providing an adhesive clot of 
chondrocytes.   Once the clot became firm, the joint was lavaged with sterile fluid and put 
through repeated range of motion to visualize retention of the graft.  Peri-operative pain 
management was achieved through use of epidural morphine and oral phenylbutazone 
administration.   Horses were box stall rested for 4 weeks post-operatively, followed by 4 
weeks of increasing amounts of walking.   
 
Synovial fluid collection and analysis 
 
Synovial fluid was collected from both femoropatellar joints immediately pre-
operatively and then at days 4, 7, 14, 28, 56 and 224 post-implantation.  Cytological analysis 
of the synovial fluid was performed with total and differential leukocyte count performed by 
Coulter (Beckman Coulter Inc., Fullerton, CA) and smear evaluation performed on Giesma-
stained smears (LIDE Laboratories Inc., Florissant, MO).   Synovial fluid was also analyzed 
for IGF-1 concentration using an ELISA (Quantikine, R&D Systems, Minneapolis, MN). 
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Arthroscopic evaluation at 8 weeks post-implantation 
 
Eight weeks post-implantation surgery, arthroscopic second-look examination of 
defects in both joints was performed.  The defects were examined, photographed and graded 
by two blinded observers (AJN,KO) using a semi-quantitative scoring system.  Individual 
parameters included area covered with smooth white repair tissue, area of defect filled, 
amount of white tissue, graft-recipient tissue integration, and subchondral bone attachment.  
Following defect evaluation, a synovial biopsy was taken and fixed in 4% paraformaldehyde 
(PFA) for histology.  Exercise was restricted to box stall rest for 2 weeks and then horses 
were allowed free pasture turnout for the remainder of the study period.     
 
Gross evaluation and specimen collection 
 
Eight months post-implantation horses were euthanized with a barbiturate overdose.  
The popliteal and inguinal lymph nodes were collected and fixed.  The lateral trochlear ridges 
were exposed, photographed, and graded using the same semi-quantitative scoring system 
described above.  An oscillating saw was used to remove a 5mm-wide rectangular 
osteochondral block containing the middle third of the repair tissue and extending 5mm 
beyond the proximal and distal edges of the graft.  The blocks were fixed in 4% PFA and then 
decalcified in 10% ethylenediamine-tetra-acetic acid (EDTA) in preparation for histology and 
immunohistochemistry.  Repair tissue from the medial third of the defect was harvested, along 
with a 5mm wide strip of perilesion cartilage and remote cartilage from the medial trochlear 
ridge.  These tissues were snap frozen in liquid nitrogen and stored in -80
o
C for later gene 
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expression and biochemical analysis.  A 3 x 10mm biopsy of the synovial membrane and 
underlying joint capsule was collected from the cranial aspect of the femoropatellar joint and 
fixed in 4% PFA.   
 
Morphologic analysis 
 
Histology 
 
 Decalcified osteochondral blocks were embedded in paraffin, sectioned at 6μm, and 
stained with hematoxylin and eosin (H&E) to evaluate morphology, and toluidine blue to 
evaluate proteoglycan content and distribution in the extracellular matrix.  Stained 
osteochondral blocks were graded by two blinded investigators (AJN, KO) using the semi-
quantitative scoring system.  Individual parameters included defect filling, chondrocyte 
predominance, perilesional cloning, subchondral bone attachment, tissue integration, surface 
fibrillation, tidemark reformation, toluidine blue staining, and collagen type II predominance.  
Synovial membrane was sectioned and stained with H&E for scoring.   Popliteal and 
ileofemoral lymph nodes collected from both limbs were also stained with H&E and scored 
by a veterinary pathologist.  The B-cell domain, T-cell domain, medullary cords and 
medullary sinuses were evaluated for inflammatory reaction. 
 
Collagen immunohistochemistry 
 
Osteochondral sections were deparaffinized, rehydrated, and treated with 5μg/mL 
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hyaluronidase (Sigma Chemical Co.) at 37
o
C for 60 min prior to blocking with normal goat 
serum.  Sections were then incubated with polyclonal rat anti-bovine type II collagen primary 
antibody (1:100) (courtesy of Dr. Michael Cremer, VA Hospital, Memphis, TN) or polyclonal 
rabbit anti-equine type I collagen primary antibody.  A secondary biotinylated goat- anti-rat or 
anti-rabbit antibody (ABC Staining System, Santa Cruz Biotechnology, Dallas, TX) was 
applied to sections, followed by streptavidin conjugated peroxidase to catalyze chromagen 
development in 3,3’-diaminobenzidine tetrachloride (Sigma-Aldrich, St Louis, MO).  Sections 
were counterstained with hematoxylin and scored based on amount and intensity of staining.   
 
Biochemical analyses 
 
Frozen lesion, perilesion and remote tissues were pulverized in liquid nitrogen in a 
freezer mill (6750 Freezer Mill, Spex Certiprep, Metuchen, NJ), lyophilized, and used for 
glycosaminoglycan (GAG), DNA, and type II collagen assays.  The dimethylmethylene blue 
(DMMB) spectrophotometric assay was used to estimate proteoglycan content in tissues.  
Chondroitin-4 sulfate was used to establish a standard curve and the OD determined at 
525nm.
22
  Total DNA content was determined from papain digested tissues that were 
incubated for 24h at 65
o
C and then mixed with bisbenzimide compound (compound 33258, 
Hoechst, Sigma-Aldrich, St Louis, MO) for quantification by fluorometric assay, using an 
excitation wavelength of 348 nm and an emission wavelength of 456 nm.   Calf thymus DNA 
was used to establish a standard curve.  Collagen type II content was assessed using a 
multispecies collagen type II ELISA (Chondrex Inc., Redmond, WA).  Lypophilized cartilage 
was pretreated and digested with guanidine, pepsin and elastase prior to assay by ELISA.  The 
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OD values were read at 490 nm.   
 
Gene Expression analysis 
 
Following pulverization in a freezer mill, tissues were mechanically homogenized and 
RNA was isolated from tissues using the PerfectPure RNA Tissue Kit (5 Prime, Gaithersburg, 
MD).  Purity and concentration of the RNA was assessed by UV microspectrophotometry 
(NanoDrop 2000 Spectrophotometer, Thermo Scientific, Waltham, MA).  Gene expression 
was quantified by real-time PCR using the Taqman One-Step RT-PCR technique (Absolute 
Quantitative PCR; ABI PRISM 7900 HT Sequence Detection System, Applied Biosystems, 
Foster City, CA).  Gene expression of IGF-I, collagen type II (col II), aggrecan (agg), and 
collagen type I (col I) was measured in lesion, perilesion and remote tissue.  All samples were 
run in duplicate.  Primer Express Software Version 2.0 (Applied Biosystems, Foster City, 
CA) was used to design equine primers and dual-labeled fluorescent probes [6-
carboxyfluorescein (FAM) as the 5’ label (reporter dye) and 5-carboxymethylrhodamine 
(TAMRA) as the 3’ label (quenching dye)].  Sequences for primers and probes were 
generated from GenBank (National Institutes of Health, Bethesda, MD) or available from 
clones with the laboratory of Dr. Alan Nixon.  Primer sequences were as follows: forward,  
5’-CGGCTTTGGTGACTCTAGATAACC-3’ and reverse, 5’-CCATGGTAGGCACAGC 
GACTA-3’ for 18S; forward, 5’-TGTACTGCGCACCCCTCAA-3’ and reverse, 5’-TTGT 
GTTCTTCAAATGTACTTCCTTCTG-3’ for IGF-I; forward, 5’-CGCTGTCCTTCGGTGT 
CA-3’ and reverse, 5’-CTTGATGTCTCCAGGTTCTCCTT-3’ for coll II; forward, 5’-
GATGCCAC TGCCACAAAACA-3’ and reverse, 5’-GATGCCACTGCC ACAAAACA-3’ 
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for aggrecan; forward, 5’-GTACCACGACCGAGCCGTAT-3’ and reverse, 5’-GATCACGT 
CATCGCACAACAC-3’ for col I.  The total copy number of mRNA was determined using a 
validated standard curve and these values were normalized to the housekeeping gene 18S.   
 
Statistical analysis 
 
Each horse in the study provided multiple observations; one chondral defect filled 
with either 1) rAAV5-IGF-I chondrocytes 2) rAAV5-GFP chondrocytes or 3) naïve 
chondrocytes, and the contralateral defect filled with fibrin vehicle.  Several of the outcome 
parameters (e.g. synovial fluid IGF-I concentration) were also repeatedly measured over time.  
In order to account for possible correlation between observations made in the same horse a 
mixed effects model, with horse as a random effect, was used for analysis.  Day was treated as 
a categorical variable.  Histograms were visually inspected for a Gaussian distribution and 
Shapiro-Wilk test was performed.  Multiple comparisons for differences in parameters for 
each interaction were made with a Tukey’s post hoc test or Bonferroni correction.  Specific 
linear contrasts were fitted to the model where appropriate to examine the nature of the 
interactions.  Statistical analysis was performed using JMP.  The level of significance was set 
at p<0.05.   
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Results 
 
Arthroscopic cartilage harvest yielded autologous chondrocytes for implantation into 
chondral defects 
 
Arthroscopic cartilage harvest of the non-weight bearing regions of the distal medial 
and lateral trochlear ridges of the talus was achieved in each horse (n=24) yielding 1.5-2.5g of 
cartilage.  Collagenase digestion of cartilage produced approximately 15 x 10
6
 chondrocytes 
that were expanded in culture to a total of 20 x 10
6
 cells prior to implantation.  Full-thickness 
chondral defects were created successfully in the lateral trochlear ridge of both femurs using 
an arthroscopically guided 15mm diameter fluted spade-bit cutter (Figure 2.1a).  Calcified 
cartilage was completely debrided from the surface of the defect using a curette.  Horses were 
randomly assigned to a treatment group in which one chondral defect was filled with 1) fibrin 
containing chondrocytes transduced with rAAV5- IGF-I (n=8), 2) fibrin containing 
chondrocytes transduced with rAAV5-GFP (positive control) (n=8) or 3) fibrin containing 
naïve, untransduced chondrocytes (n=8).  The contralateral joint of each horse was grafted 
with the autogenous fibrin vehicle alone (n=24).  All grafts stabilized within several minutes 
and remained stable while joints were moved through range of motion (Figure 2.1b). 
 
Prior to implantation of autologous chondrocytes transduced ex vivo with the rAAV5 
vector, successful rAAV5-mediated IGF-I expression by equine chondrocytes in vitro was 
demonstrated in our lab.
23
  At 14 days post-transduction, expression of IGF-I in chondrocytes 
transduced with 1 x 10
5
 vg/cell was 115-fold higher than expression of IGF-I in untransduced 
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cells as quantified by qPCR.  IGF-I concentration in the supernatants of rAAV5-IGF-I 
transduced chondrocytes was also significantly increased at 14 days post-transduction 
(55.7±8.5ng/ml) over untransduced cells (0.24±0.1ng/ml).   
 41 
 
Figure 2.1. Arthroscopic images of empty (a), implanted (b) and healing defects 8 weeks 
post-implantation (c-f) with associated healing scores (g). (a) A full-thickness, 15mm 
diameter chondral defect in the lateral trochlear ridge of the femur prior to implantation.  (b) 
The same defect after chondrocyte implantation.  The implant has been stabilized by 
polymerization of the fibrin vehicle. (c) Defect repaired with rAAV5-IGF-I transduced 
chondrocytes showing good defect fill and white “cartilage-like” tissue compared to the 
defects filled with (d) rAAV5-GFP transduced chondrocytes, (e) naïve chondrocytes or (f) 
fibrin alone. Independent parameter scores and total scores for defect healing at 8 weeks are 
shown (g) in which lower scores represent superior healing and higher scores indicate more 
abnormal tissue.  Data in the table represented as mean ± SEM.  Different letters denote 
significant differences between groups. p<0.05 
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Chondral defects repaired with rAAV5-IGF-I transduced chondrocytes had improved 
healing at 8 weeks post-implantation  
 
Short-term healing of the defects was assessed arthroscopically at 8 weeks post-
implantation at which time all defects were partially filled with repair tissue.  Representative 
images from second-look arthroscopy from all 4 treatment groups are shown (Figure 2.1c-f).  
Healing was evaluated using a scoring system based on five parameters (area covered with 
smooth white repair tissue, area of defect filled, amount of white tissue, graft-recipient tissue 
integration, and subchondral bone attachment) yielding independent scores for each category 
and a composite score.  Healing scores closest to zero reflected repair tissue most similar to 
native cartilage, while higher scores reflected the most abnormal repair tissue.  Defects 
repaired with rAAV5-IGF-I chondrocytes had significantly more area covered with smooth 
repair tissue (Figure 2.1c) than defects repaired with rAAV5-GFP chondrocytes (Figure 
2.1d) or fibrin alone (Figure 2.1f) and this was reflected by rAAV5-IGF-I defects having 
significantly lower (better) healing scores (Figure 2.1g).  Additionally, rAAV5-IGF-I treated 
defects had significantly more area covered with white repair tissue (Figure 2.1c) than defects 
repaired with rAAV5-GFP chondrocytes (Figure 2.1d) or fibrin alone (Figure 2.1f).  Overall, 
defects repaired with rAAV5-IGF-I had the lowest (best) total arthroscopic healing score 
(mean±SEM; 5.35±1.30) compared to defects filled with rAAV5-GFP (11.05±1.30), naïve 
chondrocytes (8.56±1.30) and fibrin alone (10.79±0.73) (Figure 2.1g).  The differences 
between rAAV5-IGF-I and rAAV5-GFP or fibrin alone were significant. 
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rAAV5-IGF-I transduced chondrocytes increase synovial fluid IGF-I concentration 
without causing significant inflammatory changes 
 
In order to assess transgene expression following chondrocyte implantation, IGF-I 
content in the synovial fluid of femoropatellar joints was analyzed over time using a mixed 
effects model to account for repeated measures.  The effect of day (F ratio = 90.6; p<0.0001) 
and treatment group (F ratio = 3.8; p<0.012) were both significant, as was the interaction 
between day and treatment group (F ratio = 2.2; p<0.004).  IGF-I content in the synovial fluid 
increased in all treatment groups immediately post-operatively with return to baseline by day 
56 (Figure 2.2).  Synovial fluid IGF-I concentrations obtained from femoropatellar joints 
treated with rAAV5-IGF-I chondrocytes was significantly increased over joints treated with 
rAAV5-GFP chondrocytes (Bonferroni adjusted p=0.025, linear contrast) and fibrin alone 
(Bonferroni adjusted p<0.0001, linear contrast) at day 4 (Figure 2.2).  At day 7 post-
operatively, IGF-I concentrations obtained from joints treated with rAAV5-IGF-I 
chondrocytes were still significantly increased over joints treated with rAAV5-GFP 
chondrocytes (Bonferroni adjusted p=0.014, linear contrast) and fibrin alone (Bonferroni 
adjusted p=0.0006, linear contrast) (Figure 2.2).  IGF-I levels were highest at 4 days post-
operatively with rAAV5-IGF-I treated joints having 202.4 ng/ml (± 24.4) compared to 145.3 
ng/ml (±17.7) in rAAV5-GFP joints, 172.2 ng/ml (±85.4) in naïve chondrocyte joints and 
125.7 ng/ml  (±12.9) in fibrin joints (Figure 2.2).   
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Figure 2.2. Concentrations (means ± SEM) of IGF-I in the femoropatellar synovial fluid over 
time from joints treated with rAAV5-IGF-I transduced chondrocytes, rAAV5-GFP transduced 
chondrocytes, naïve chondrocytes, or fibrin alone. * Significant difference between rAAV5-
IGF-I treated joints compared to rAAV5-GFP and fibrin treated joints. p<0.05 
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The correlation between IGF-I concentrations in femoropatellar synovial fluid and 
healing of defects was also evaluated.  There was a weak, but significant (p<0.05), correlation 
between peak IGF-I concentrations at day 4 and 7 with 8 week arthroscopic healing scores, 8 
month gross healing scores and  total histological scores.   Horses with higher IGF-I 
concentrations post-implantation had better healing in the short- and long-term.   
 
Further analysis of synovial fluid composition was performed to assess the 
inflammatory response of the joint to the vectors.  The nucleated cell count (NCC) increased 
over baseline in femoropatellar joints of all treatment groups 4 days post-operatively, 
however, these increases were only significantly different compared to preoperative NCCs in 
horses treated with rAAV5-GFP chondrocytes (4712.5±1366.8cells/μL) and fibrin alone 
(3890.5±709.8 cells/μL) (Figure 2.3).  Horses treated with rAAV5-GFP chondrocytes had a 
significantly higher NCC 4 days post-operatively compared to rAAV5-IGF-I 
(2616.7±360.0cells/μL; Bonferroni adjusted p=0.0042, linear contrast) and naïve 
chondrocytes (2871.4±260.7cells/μL; Bonferroni adjusted p=0.015, linear contrast) (Figure 
2.3a).  All NCCs decreased by day 7 postoperatively with no significant differences between 
pre- and postoperative counts.  Synovial total protein (TP) levels increased significantly over 
baseline in all femoropatellar joints immediately following surgery with no significant 
differences between treatment groups (Figure 2.3b).  Total protein concentrations remained 
significantly elevated above preoperative levels until day 56 postoperatively in all  groups 
except rAAV5-IGF-I treated joints in which total protein concentrations returned to baseline 
by day 28 (Figure 2.3b).  
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Figure 2.3. Synovial fluid composition following chondrocyte implantation including (a) 
nucleated cell count (NCC) and (b) total protein (g/dl).  No significant differences were noted 
between groups.   
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rAAV5-IGF-I transduced chondrocytes led to improved long-term healing with 
increased collagen type II content 
 
Long-term healing of defects was assessed at 8 months post-implantation by means of 
gross and histologic healing scores.  Gross images of healing defects from the 4 treatment 
groups (Figure 2.4a-d) revealed improved healing of rAAV5-IGF-I treated defects.  
Individual parameter and total gross scores presented in Figure 2.4e show defects repaired 
with rAAV5-IGF-I chondrocytes had significantly lower (better) total healing scores 
(mean±SEM; 4.13±0.69) than defects repaired with naïve chondrocytes (6.99 ±0.69) and 
fibrin alone (6.75 ±0.39).  rAAV5-IGF-I treated defects had lower total healing scores than 
defects treated with rAAV5-GFP chondrocytes (5.75; SE±0.69) but this difference did not 
reach significance.  Improved gross healing in rAAV5-IGF-I defects was reflected in the 
histological healing observed in osteochondral sections stained with hematoxylin & eosin.  
Representative images of all 4 treatment groups are shown (Figure 2.5a-d).  Histological 
scoring at 8 months post-implantation revealed significantly improved (lower) total healing in 
rAAV5-IGF-I treated defects (mean±SEM; 12.47±1.26) compared to defects treated with 
naïve chondrocytes (18.32±1.26) or fibrin alone (18.58±0.77) (Table 2.1).  Although total 
healing scores from defects repaired with rAAV5-IGF-I (12.47±1.26) were better than those 
repaired with rAAV5-GFP (15.97±1.26), these differences were not significant (Table 2.1).   
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Figure 2.4. Gross appearance of healing defects 8 months post-implantation (a-d) with 
associated gross healing scores (e).  The gross images (a-d) and arthroscopic images in Fig. 
2a-d are taken from the same defects.  (a) Gross appearance of a defect repaired with rAAV5-
IGF-I transduced chondrocytes compared to, (b) a defect repaired with rAAV5-GFP, (c) a 
defect repaired with naïve chondrocytes, and (d) a defect repaired with fibrin alone.  
Independent parameter scores and total scores for defect healing at 8 months are shown (e) in 
which lower scores represent superior healing and higher scores indicate more abnormal 
tissue.  Data in the table represented as mean ± SEM.  Different letters denote significant 
differences between groups. p<0.05 
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Figure 2.5. Photomicrographs of osteochondral sections taken from repair tissue at 8 months 
post-implantation and stained with hematoxylin and eosin.   (a) rAAV5-IGF-I transduced 
chondrocytes show more chondrocyte predominance, improved tissue organization and less 
fibrous tissue than defects treated with either (b) rAAV5-GFP transduced chondrocytes, (c) 
naïve chondrocytes, or (d) fibrin alone.   Inset boxes are enlarged to show tissue architecture 
and attachment at the subchondral bone interface. (Bar = 5mm; Inset bar = 500μm) 
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Table 2.1. Histologic healing scores of lesions at 8 months post-implantation 
 
Treatment 
Group 
Defect 
Filling 
(%) 
Chond 
Predom 
Perilesion 
Cloning 
Subchond 
Bone Attach 
Perimeter 
Attach 
Surface 
Fibri-
llation 
Tidemark 
Tol Blue 
Staining % 
Coll type 
II IHC 
Total 
Score 
rAAV5-IGF-I 
0.92±0.42 1.76±0.22a 0.35±0.2a 0.65±0.47 0.57±0.22 0.58±0.29 2.25±0.17a 3.23±0.2 a 2.09±0.33a 12.47±1.26a 
rAAV5-GFP 
1.53±0.42 2.38±0.22ab 0.5± 0.22a 1.30±0.47 0.82±0.22 1.02±0.29 2.25±0.17a 3.50±0.2 ab 2.63±0.33ab 15.97±1.26ab 
Naïve Chond 
1.55±0.42 2.49±0.22ab 0.78±0.22ab 1.30±0.47 1.23±0.22 1.52±0.29 2.63±0.17ab 3.90±0.2 ab 3.02±0.33ab 18.32±1.26b 
Fibrin 
1.25±0.25 2.71± 0.12b 1.25±0.12b 1.08±0.27 1.08±0.13 1.29±0.18 2.88±0.9b 3.88±0.11 b 3.17±0.19b 18.58±0.77b 
 
Data presented as mean ± SEM. Results analyzed using a mixed effects model with horse as a random effect.  Different letters 
denote significant differences between groups. p<0.05 
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Proteoglycan content (μg glycosaminoglycan/mg cartilage) of repair tissue at 8 
months post-implantation was significantly higher in rAAV5-IGF-I treated defects 
(mean±SEM; 24.5±2.32μg/mg) compared to rAAV5-GFP treated defects (14.5±2.48μg/mg), 
however, there were no significant differences in proteoglycan between rAAV5-IGF-I, naïve 
chondrocytes (19.0±2.30μg/mg) and fibrin treated defects (23.3±1.43μg/mg) (Table 2.2).  
Interestingly, rAAV5-IGF-I had the most toluidine blue staining on histological samples, 
although these differences were only significant between rAAV5-IGF-I treated defects and 
fibrin treated defects (Table 2.1).  Across all 4 treatment groups, proteoglycan content in 
repair tissue (20.3±2.46μg/mg) was approximately 1/3 the amount of proteoglycan content 
present in perilesion (67.4±2.53μg/mg) and remote cartilage (63.9±1.63μg/mg) supportive of 
moderate regeneration of the ECM at 8 months.  There were no differences in DNA content of 
repair tissue across the 4 treatment groups (Table 2.2).   Repair tissue DNA content was less 
than that of perilesion or remote tissues in all 4 groups indicating that repair tissue had 
decreased cellularity compared to native cartilage.   
 
Collagen type II immunoreaction was more extensive in rAAV5-IGF-I treated defects 
compared to the other treatment groups (Figure 2.6a-d).  Immunohistochemistry scoring of 
histological samples supported this finding with more collagen type II content in rAAV5-IGF-
I treated defects, although these differences were only significant when compared to fibrin 
treated defects (Table 2.1).  Increased collagen type II content in rAAV5-IGF-I treated 
defects was confirmed by ELISA, with significantly more collagen type II in rAAV5-IGF-I 
treated defects compared to defects treated with rAAV5-GFP chondrocytes, naïve 
chondrocytes or fibrin alone (Figure 2.7).  
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Table 2.2. Biochemical analysis of lesion cartilage 8 months post-implantation. 
 
Data presented as mean ± SEM. Results analyzed using a mixed effects model with horse as a random effect.  Different letters 
denote significant differences between groups. p<0.05 
Treatment Group Glycosaminoglycan DNA 
rAAV5-IGF-I 24.5 (2.32)
a 
7.34 (1.30) 
rAAV5-GFP 14.5 (2.48)
b 
4.34 (1.14) 
Naïve Chondrocytes 19.0 (2.30)
ab 
5.82 (1.30) 
Fibrin 23.3 (1.43)
ab 
7.32 (0.71) 
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Figure 2.6. Collagen type II formation in repair tissue at 8 months post-implantation.  (a) 
rAAV5-IGF-I transduced chondrocytes show increased collagen type II (brown staining) 
compared to defects repaired with (b) rAAV5-GFP transduced chondrocytes, (c) naïve 
chondrocytes, or (d) fibrin alone. (Bar = 5mm; Inset bar = 500μm) 
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Figure 2.7. Log transformed (± SEM) collagen type II content in repair tissue in rAAV5-IGF-
I, rAAV5-GFP, naïve chondrocyte and fibrin treated (control) defects.  Tukey’s classification 
letters indicate significant differences between treatment groups.  
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Expression of genes associated with hyaline cartilage including IGF-I, aggrecan, 
collagen type II and collagen type I were assessed in repair tissue, perilesion tissue and 
remote tissue by qRT-PCR.  At 8 months post-implantation, there were no differences in 
expression of IGF-I, aggrecan, collagen type II or collagen type I in repair tissue from defects 
repaired with rAAV5-IGF-I chondrocytes, rAAV5-GFP chondrocytes, naïve chondrocytes or 
fibrin alone (Figure 2.8a-d).  No differences in gene expression were noted in the perilesion 
or remote tissue from between any of the treatment groups. 
 
Implantation of chondrocytes transduced ex vivo with a rAAV5 vector did not cause a 
significant inflammatory response in synovium  
 
Synovial biopsies were collected during arthroscopic examination at 8 weeks post- 
implantation and at 8 months post-implantation.  Synovium was evaluated and scored for 
changes in villus architecture, subintimal fibrosis, intimal thickening, increased vasculature, 
or inflammatory cell infiltration indicative of an inflammatory response.  Synovial biopsies 
collected at 8 weeks and 8 months post-implantation showed no significant differences 
between treatment groups.  Treatment with rAAV5 did not appear to cause a significant 
inflammatory reaction in the synovial tissue of the femoropatellar joint consistent with the 
synovial fluid profiles observed between the groups.  Biopsies of the ileofemoral and popliteal 
lymph nodes (main draining lymph nodes of the femoropatellar joints) taken at necropsy 
showed significantly more reaction in ileofemoral than popliteal lymph nodes within in all 
treatment groups, however, no differences were noted in popliteal or ileofemoral lymph node 
reactivity between any of the treatment groups.      
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Figure 2.8. Quantitative polymerase chain reaction (qPCR) data showing expression of (a) 
IGF-I, (b) collagen type II, (c) aggrecan, and (d) collagen type I in repair tissue from defects 
treated with rAAV5-IGF-I chondrocytes, rAAV5-GFP chondrocytes, naïve chondrocytes or 
fibrin alone (mean; min-max).  No significant differences were noted between the 4 treatment 
groups (18S RNA, 18S ribosomal ribonucleic acid). 
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Discussion 
 
Implantation of autologous chondrocytes transduced with rAAV5-IGF-I ex vivo 
resulted in improved repair of full-thickness chondral defects of the lateral trochlear ridge of 
the horse, both in the short-term (8 weeks post-implantation), and long-term (8 months post-
implantation).  These grafted defects showed features of hyaline-like repair tissue including 
hyaline-like tissue architecture, chondrocyte predominance and collagen type II abundance.  
The total histologic scores of rAAV5-IGF-I treated defects were significantly improved over 
defects treated with naïve chondrocytes and fibrin alone.  Collagen type II 
immunohistochemistry scores were also significantly improved in rAAV5-IGF-I treated 
defects compared to defects treated with fibrin alone.  These results were further validated by 
collagen type II ELISA that showed significantly increased collagen type II protein in 
rAAV5-IGF-I treated defects over defects treated with rAAV5-GFP chondrocytes, naïve 
chondrocytes or fibrin alone.  Upregulation of collagen type II in chondrocytes with IGF-I 
supplementation has been shown previously.
24,25
  The increased collagen type II levels in our 
study are likely due to overexpression of IGF-I by the rAAV-IGF-I vector.   
 
IGF-I has been shown to play a major role in articular cartilage homeostasis and 
anabolism.
14,26
 The addition of exogenous IGF-I to chondrocyte grafts has been shown to 
improve repair of chondral defects in vivo, however, incomplete chondrogenesis was noted at 
8 months.
12
  We sought to increase longevity of IGF-I supplementation in repair tissue 
through use of a rAAV5 vector.    Significantly increased levels of IGF-I protein were noted 
in the synovial fluid of rAAV5-IGF-I treated joints at 4 and 7 days post-implantation 
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suggestive of transgene expression.  Interestingly, there was a significant correlation between 
IGF-I concentrations at days 4 and 7, and healing at 8 weeks and 8 months.  Horses with 
higher IGF-I concentrations post-implantation were more likely to have superior healing. The 
decrease in synovial fluid IGF-I concentration after day 7 was not unexpected as the 
femoropatellar joint is a voluminous joint and the chondral defect containing transduced cells 
is relatively small.  The inevitable dilution of IGF-I produced by transduced cells would make 
increases in IGF-I protein difficult to detect unless they were quite large. Expression profiles 
from chondrocytes transduced in vitro with rAAV5-IGF-I showed significantly elevated IGF-
I concentrations up to 28 days.
23
 Alternatively, it is possible that IGF-I excretion into the 
synovial fluid was reduced due to early cessation of transgene expression, death of implanted 
chondrocytes or maturation of the graft leading to decreased penetrability.  Loss of transgene 
expression can occur due to cytotoxic T cell responses that destroy transduced cells.  
Although there did not appear to be a significant inflammatory response in treated joints, 
specific immune responses were beyond the scope of this experiment and should be 
considered as a potential cause of loss of transgene expression in future experiments.  Repair 
tissue collected at 8 months post-implantation from the 4 treatment groups did not show any 
significant differences in IGF-I transcriptional activity based on qPCR which supports loss of 
transgene overexpression in the long-term.  Biopsies of repair tissue at earlier time points 
could shed light on longevity of IGF-I expression, however, disruption of the repair site is a 
major concern.   
 
Adeno-associated virus has been touted as an ideal viral vector due to its lack of 
pathogenicity, ability to transduce non-dividing cells, and prolonged expression.
17
  Tissue 
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tropism has been shown for several AAV serotypes and these affinities are likely species-
specific.  rAAV5 provided excellent transduction of equine chondrocytes in this study, based 
on evidence from fluorescent microscopy showing GFP expression in pre-implantation 
monolayer cultures.  Other serotypes, including rAAV2, have been evaluated for transduction 
efficiency of articular cells, however, preliminary data in our laboratory comparing rAAV2 
and rAAV5 revealed optimal transduction of chondrocytes by rAAV5 at a dose of 
10
5
vg/cell.
23
   
 
In the past, similar studies in the horse have used allogeneic chondrocytes as a source 
for cell-based repair.
8,12
  We investigated the use of autologous chondrocytes in order to 
eliminate potential host immune reaction to allogeneic cells.  Although autologous cells do 
not incite an immune response, this cell source is not without concerns.  Donor site morbidity 
is a major problem in human ACI.
27
  In our case, 1.5-2.5g of cartilage was removed from the 
distal talus and although these donor sites are non-weight bearing surfaces in the horse, such 
extensive cartilage debridement risks long-term negative effects in the joint.  The expansion 
of chondrocytes in culture following cartilage digestion is associated with dedifferentiation 
and loss of the chondrocyte phenotype.
28-30
  It is difficult to find an ideal balance between 
limiting the amount of cartilage harvested in order to decrease donor site morbidity, while 
simultaneously obtaining enough tissue that extensive expansion, and thereby 
dedifferentiation, is not required to attain adequate cell numbers for implantation.  It is worth 
noting that redifferentiation of chondrocytes has been shown to occur rapidly in three-
dimensional cultures 
31
 and could be expected to occur in the fibrin complexes used in this 
study.   
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The minimally invasive nature of chondrocyte implantation in this study is a major 
advantage of this technique.  Transduced chondrocytes were able to be stably implanted into 
chondral defects using a self-polymerizing cell/fibrinogen mixture and calcium-activated 
thrombin under arthroscopic guidance.  Eliminating the need for an arthrotomy to access 
cartilage defects greatly decreases post-operative morbidity and healing times.  Although both 
cartilage harvest and chondrocyte implantation were performed using minimally invasive 
techniques, donor site morbidity and need for a second surgery are ongoing concerns.  
Considering the potential detrimental consequences of cartilage harvest, alternative cell 
sources for cartilage repair, such as chondrogenically differentiated stem cells may provide a 
superior treatment method.  This cell source would eliminate both donor site morbidity and 
the need for multiple surgeries.  
 
This well-established equine model likely provides the closest approximation to 
cartilage repair in man and is a more robust model than more commonly used small animal 
models.  The cartilage of the equine lateral trochlear ridge has approximately the same 
thickness (2-3mm) and load bearing characteristics as human femoral condyles.
32
  Inter-
animal variability plays an important role in gene therapy; host differences can affect 
transduction efficiency, transgene expression and survival of transduced cells.  In this study, 
we observed moderate inter-animal variability; however, the response to AAV-transduced 
autologous chondrocytes in man will likely be far more variable as the population is more 
diverse.  Additionally, there appears to be significant differences in the immune response to 
AAV between humans and horses. For example, cytotoxic CD8
+
 T-cell responses have been 
shown in humans
33
 but have not been demonstrated in horses.  
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Although improved healing was noted in the rAAV5-IGF-I treated defects, the 
transition from “hyaline-like” to hyaline repair tissue remains challenging.  At 8 months post-
implantation graft-host integration was complete in some histological sections of treated 
defects, however, full integration around the entire perimeter of the defects was not observed, 
which would likely limit durability of the repair tissue.  It is possible that longer-term 
evaluation of the grafts may have shown enhanced integration.  Although full integration was 
not observed, it is noteworthy that all grafts remained stable throughout the 8 month study 
period during which horses had free access to exercise placing substantial load and stress on 
the repair tissue.  rAAV5-IGF-I repair tissue had superior smoothness and collagen type II 
content compared to other treatments, however, the rAAV5-IGF-I neocartilage was not 
consistently smooth (Figure 2.5a) and collagen type II did not appear to be evenly distributed 
(Figure 2.6a).  This may be explained by differences in transgene expression of transduced 
chondrocytes throughout the depth of the implant.  The superficial layer of the repair tissue 
undergoes more intense wear post-implantation which could increase cell death and decrease 
ECM production.   
 
In summary, minimally invasive implantation of autologous chondrocytes transduced 
ex vivo with rAAV5-IGF-I appears to improve long-term healing of full-thickness chondral 
defects in the equine model. Important features of hyaline-like repair tissue were noted in 
rAAV5-IGF-I treated lesions including hyaline-like tissue architecture, predominance of 
chondrocytes as the main cell type, and an increased abundance of collagen type II.  
Importantly, rAAV5 transduced chondrocytes appeared to have little adverse effect on joints 
as there were no significant alterations in synovial fluid composition, no significant 
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differences noted in synovial biopsies, and all treated horses remained clinically sound.  
Although this study showed improved repair with genetically-modified chondrocytes, return 
to native tissue continues to be a significant challenge.  Further investigation into genetically-
enhanced chondrocytes that concurrently limit catabolic cytokine abundance may improve the 
hyaline character of the repair more profoundly.   
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CHAPTER THREE 
 
 
CATABOLIC CYTOKINE SUPPRESSION IN CHONDROCYTES BY rAAV2 DELIVERY 
OF A SHORT HAIRPIN RNA INTERENCE MOTIF TARGETING INTERLEUKIN-1β 
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Abstract 
 
Post-traumatic activation of the catabolic cascade plays a major role in progressive 
degradation of articular cartilage.  Interleukin-1β (IL-1β) is a primary initiator of the catabolic 
axis and is significantly upregulated in chondrocytes following injury.  IL-1β in turn activates 
key degradative enzymes, including matrix metalloproteinases (MMPs) and aggrecanases 
(ADAMTS), and other pro-inflammatory mediators such as PGE2, that contribute to 
breakdown of the extra-cellular matrix (ECM). Loss of integrity of the ECM precipitates 
osteoarthritis (OA), a prevalent and irreversible disease that currently lacks any curative 
treatment.  Post-transcriptional silencing of IL-1β, mediated by RNA interference, may offer a 
sustainable, effective reduction in IL-1β expression and thereby, limit the downstream 
degradative effects.  We hypothesized that transduction of chondrocytes, using an rAAV2 
vector expressing a short hairpin IL-1β RNA interference motif would lead to a significant 
decreases in IL-1β expression, as well as decreased expression of other catabolic enzymes 
including MMPs and aggrecanases.  Chondrocyte monolayer cultures were transduced with 
rAAV2-tdT-shIL-1β in serum-free media.  The fluorescent protein, tdTomato, was used to 
determine transduction efficiency via flow cytometry and fluorescent microscopy.  Cells were 
stimulated with lipopolysaccharide (LPS) 48 hours following transduction.  After 24 hours of 
LPS stimulation, supernatants were collected and cells lysed for RNA isolation and gene 
expression analysis.  rAAV2-tdT-shIL-1β transduction of chondrocytes led to significantly 
decreased expression of IL-1β, TNF-α and ADAMTS-5, compared to untransduced, LPS-
stimulated chondrocytes.  PGE2 synthesis was also significantly downregulated.  This study 
showed effective silencing of IL-1β using a rAAV2 vector expressing a short hairpin IL-1β 
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sequence.  Additionally, we found significant downstream effects of IL-1β silencing, 
including decreased expression of key catabolic factors, TNF-α and ADAMTS-5.  Gene 
therapy targeting catabolic cytokines through RNA interference may provide a promising 
treatment modality for the OA joint.   
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Introduction 
 
Osteoarthritis (OA) is a prevalent, debilitating disease that currently lacks any 
effective treatment and often culminates in total joint replacement surgery.  It is characterized 
by progressive degradation of the extra-cellular matrix (ECM) leading to joint swelling, 
reduced mobility and pain.  Chondrocytes are the sole cell type responsible for maintaining 
the integrity of the ECM, and disruption of chondrocyte metabolism following trauma to the 
articular surface is considered a pivotal step in deterioration of the osteoarthritic joint.  
Perturbations in gene expression patterns of chondrocytes, including increased expression of 
catabolic cytokines and degradative enzymes, have been shown to cause slow destruction of 
the ECM.
1
   
 
Interleukin-1β (IL-1β), a pro-inflammatory cytokine, is considered a primary 
instigator of cartilage degradation
2-4
 and is upregulated in equine OA chondrocytes and 
synovial fluid from OA joints.
5
  IL-1β acts through autocrine and paracrine signaling 
pathways to increase synthesis of degradative enzymes, including MMPs and aggrecanases, 
that actively breakdown the ECM.
6
  Simultaneously, IL-1β decreases expression of collagen 
type II and inhibits aggrecan synthesis.
7,8
  Inflammatory mediators, such as prostaglandin E2 
(PGE2)
9
 and nitric oxide (NO),
10
 are also increased by IL-1β and likely play a significant role 
in the pain response associated with OA. 
 
The beneficial role of IL-1 receptor antagonist protein (IL-1Ra) has received ample 
attention as it decreases the degradative effects of IL-1β through competitive binding of IL-1 
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receptors.
11-13
  A potential impediment to IL-1Ra therapy is the requirement of 100-fold, or 
greater, excess of IL-1Ra over IL-1 to achieve effective antagonism.
14
  Maintaining sufficient 
IL-1Ra concentrations in the synovial fluid is difficult, especially considering the positive 
feedback loop exhibited by IL-1β.15,16  Post-transcriptional silencing of IL-1β through RNA 
interference (RNAi) may offer a superior method of controlling the catabolic cascade 
involved in joint injury and OA.  Small interfering RNAs (siRNAs) were originally 
investigated as therapeutic modalities.  However, more recently viral vectors have been 
explored as they provide long-term, sustainable expression of short hairpin RNAs. 
 
A gene therapy approach for treating OA is attractive as the disease often affects a 
single joint that can be treated locally with an intra-articular injection of a vector over-
expressing a therapeutic transgene.  Sustained, vector-mediated knockdown of IL-1β 
expression in perturbed chondrocytes may ameliorate degradation of the ECM by helping to 
restore normal physiologic balance in cartilage, thereby providing a therapeutic option for OA 
joints.  Recombinant adeno-associated virus vectors (rAAV) are ideal candidates for intra-
articular gene therapy as they can invade non-dividing cells, are non-pathogenic, and 
replication deficient.
17
   Transduction of articular tissues, including chondrocytes, 
synoviocytes and intact cartilage, by rAAV vectors has been well-demonstrated.
18-20
   
 
The objective of this study was to evaluate the effects of rAAV2 mediated knockdown 
of IL-1β on gene expression and protein synthesis in chondrocytes cultured in an OA model.   
We hypothesized that transduction of chondrocytes with rAAV2-shIL-1β prior to stimulation 
with lipopolysaccharide (LPS) would effectively silence IL-1β and would in turn decrease 
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expression of catabolic cytokines, degradative enzymes, and inflammatory mediators involved 
in the IL-1β signaling pathway. We also hypothesized that IL-1β interference would rescue 
suppression of key matrix proteins, including collagen type II and aggrecan, that occurs 
following LPS stimulation. 
 
Materials & Methods  
 
Tissue culture 
 
Cartilage was harvested from the articular surface of three young Thoroughbred horses 
(mean age = 1.23 years) and digested in 0.075% collagenase (Worthington Biochemical, 
Lakewood, NJ) as previously described.
21
  Following digestion, cells were filtered and 
centrifuged at 300 g for 5 minutes.  Cell pellets were washed and cells counted before plating 
in 24-well plates (Corning Inc., Corning, NY) at a density of 1 x 10
5
 cells/cm
2
.  Chondrocytes 
were cultured in Ham’s F12 medium (Corning Inc., Corning, NY) supplemented with 10% 
fetal bovine serum (FBS), 50μg/ml ascorbic acid,  30μg/ml α-ketoglutarate, 300μg/ml L-
glutamine, 100units/ml penicillin/streptomycin, and 25mM HEPES (Gibco-Life Technology, 
Grand Island, NY) and allowed to adhere for 48 hours.  Prior to any transfection or 
transduction procedure, medium was replaced with serum-free Opti-MEM (Invitrogen, Grand 
Island, NY) for 4 hours.  All chondrocyte experiments were performed in triplicate. 
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siRNA and plasmid screening 
 
Three different siRNA sequences targeting IL-1β were designed by Ambion (Grand 
Island, NY) using their proprietary software and three siRNA sequences were designed using 
the online algorithm at the Public TRC Portal (www.broadinstitute.org/rnai/public/seq/search) 
(Table 3.1).   These six siRNA sequences were synthesized (IDT, Coralville, IA) and 
evaluated for knockdown efficiency in monolayer cultures using chondrocytes from 3 
different horses.  Cells were transfected with siRNA in serum-free medium using 
DharmaFECT transfection reagent (Thermo Scientific, Waltham, MA).  Following 
transfection, chondrocytes were stimulated with 50μg/ml E. Coli O55:B5 lipopolysaccharide 
(LPS; Sigma-Aldrich, St. Louis, MO) in serum-free medium.  After 24 hours, cells were lysed 
and RNA isolated using the PerfectPure RNA kit (5 Prime, Gaithersburg, MD). The two 
siRNA sequences with the most profound decrease in IL-1β expression were then designed as 
short hairpins (sh) by addition of a loop, poly A tail, and restriction sites.  The shRNA 
sequences were synthesized as dsDNA (IDT, Coralville, IA) and ligated into the U6 
promoter-driven pSilencer 2.1-U6 Puro plasmid (Life Technologies, Grand Island, NY).  
Knockdown efficiency of the 2 shRNA sequences was determined in monolayer chondrocytes 
following transfection of cells using FuGENE HD Transfection Reagent (Promega, Madison, 
WI).  
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Table 3.1. siRNA sequences targeting IL-1β 
siIL-1β Sequence Name Sequence 
#1 5’-CCAGUGACAUGAUGACUUA-3’ 
#2 5’-UCCGGGACAUAUACCAUAAAU-3’ 
#3 5’-GCUUCAAUUCUCCCACCAA-3’ 
#4 5’-GACAACUGGGAUGAUGAUUAU-3’ 
#5 5’-AAGUCAGUUAUGUCCCGGCCG-3’ 
#6 5’-CCAGUUUAAUUUGGACUAG-3’ 
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Adeno-associated viral vector production 
 
The most efficient shIL-1β sequence and the red fluorescent protein, tdTomato (tdT), 
were subcloned into the rAAV transfer plasmid pHpa-trs-SK.  The transgenes were flanked 
by inverted terminal repeats; tdT was under control of the cytomegalovirus (CMV) early 
promoter and shIL-1β was under control of the U6 promoter.  scAAV2-tdT-shIL-1β was 
generated by the Research Vector Core at The Children’s Hospital of Philadelphia (CHOP) in 
HEK293 cells using the triple plasmid transfection method in which cells were transfected 
with three different plasmids. The plasmids included: 1) rAAV-tdT-shIL-1β construct, 2) the 
AAV rep and cap genes and 3) the adenovirus helpervirus.  
 
AAV transduction and LPS stimulation of chondrocytes 
 
Chondrocytes were cultured in monolayer as described above for 48 hours.  Four 
treatment groups were evaluated: 1) no vector, no LPS (C); 2) no vector, LPS (LPS); 3) 
rAAV2-tdT-shIL-1β, no LPS (shIL-1β); 4) rAAV2-tdT-shIL-1β, LPS (shIL-1β+LPS).  
Medium was changed to serum-free Opti-MEM 4 hours prior to transduction.  Chondrocytes 
were transduced with 1 x 10
5
 viral genomes/cell for 2 hours at 37
o
C.  Transduction medium 
was then replaced with fresh Opti-MEM and cultures were maintained for 48 hours prior to 
LPS stimulation.  Chondrocytes were stimulated with 50μg/ml of LPS for 24 hours prior to 
collection and further analysis.   
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Flow cytometry and fluorescent microscopy 
 
Chondrocytes were trypsinized, washed, and suspended in 0.5% PBS/BSA 24, 48 and 
72 hours post-transduction for flow cytometric analysis using a FACSCanto II flow cytometer 
(BD Biosciences, San Diego, CA).  tdTomato expression was quantified using a 585/42 filter 
to measure fluorescence. Untransduced chondrocytes were used to set fluorescent gates in 
order to account for autofluorescence.   Fluorescent microscopy, to visually assess 
transduction of cells, was also performed at these time points (Olympus Inverted Microscope 
IX73, Olympus, Center Valley, PA).   
 
Gene expression  
 
Chondrocytes were lysed and RNA was isolated using the PerfectPure RNA kit (5 
Prime, Gaithersburg, MD).   Purity and concentration of the RNA was assessed using UV 
microspectrophotomerty (NanoDrop 2000 Spectrophotometer, Thermo Scientific, Waltham, 
MA).  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess gene 
expression with all samples run in duplicate (ABI PRISM 7900 HT Sequence Detection 
System, Applied Biosystems, Foster City, CA).  Equine primers and dual-labeled fluorescent 
probes [6-carboxyfluorescein (FAM) as the 5’ label (reporter dye) and 5-
carboxymethylrhodamine (TAMRA) as the 3’ label (quenching dye)] were used.  Sequences 
for primers and probes were generated from GenBank (National Institutes of Health, 
Bethesda, MD) or available from clones with the laboratory of Dr. Alan Nixon.  Primer 
sequences are presented in Table 3.2. Total copy number of mRNA was determined using a 
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validated standard curve and these values were normalized to the housekeeping gene, 18S.   
 
PGE2 synthesis 
 
 Medium was collected from monolayer cultures 24 hours following LPS stimulation 
and PGE2 concentration was quantified using a competitive enzyme immunoassay (Enzo Life 
Sciences, Farmingdale, NY).  Optical density was measured using a Tecan microplate reader 
at 405nm with wavelength correction set at 570nm. 
 
Statistics 
 
Triplicate culture samples for n=3 horses were performed.  Flow cytometry data was 
expressed as mean percentage ± SEM.  Changes in gene expression were shown as mean 
percentage change ± SEM relative to LPS chondrocytes.  Statistical analysis was performed 
using a one-way analysis of variance (ANOVA) to compare differences between the four 
different treatment groups.  Pairwise comparisons were made using a Tukey’s post hoc test. 
Statistical analysis was performed using JMP. The level of significance was set at p<0.05. 
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Table 3.2. Equine primer sequences used to analyze gene expression 
Gene Forward Primer Sequence Reverse Primer Sequence Probe Sequence 
18S 5’-CGGCTTTGGTGACTCTAGATAACC-3’ 5’-CCATGGTAGGCACAGCGACTA-3’ 5’- TGGCGTTCAGCCACCCGAGATT-3’ 
IL-1β 5’-CGTCTCCCAGAGCCAATCC-3’ 5’-CACCAGGCTGACTTTGAGTGAGT-3’ 5’-CCCTCTGCTGAGCAGGGCCTCTC-3’ 
TNF- α 5’-CAGCCGCTTAGCTGTCTCCTA-3’ 5’-GTGTGGCAAGGGCTCTTGAT-3’ 5’-CCGTCCAAGGTCAACCTCCTCTCTGC-3’ 
ADAMTS-4 5’-CCCTGGTCTCCGAAACCTCTA-3’ 5’-TATTCACCATTGAGGGCATAGGA-3’ 5’-CTGGCCCTGAAGCTCCCAGATGG-3’ 
ADAMTS-5 5’- CAGACGTTGGGACCATATGCT-3’ 5’-TGCGTGGAGGCCATCAT-3’ 5’-AGAGCGCAGCTGTGCTGTGATTGAA-3’ 
MMP-3 5’-CTTATCAAAAATGGCTGCGTCTATT-3’ 5’-GCAGAGACAGTGTTTTCATTTTTAAG-3’ 5’- CCTCTCGGGTAACCCGCTTGTTCC-3’ 
MMP-13 5’-TGAAGACCCGAACCCTAAACAT-3’ 5’-GAAGACTGGTGATGGCATCAAG-3’ 5’-CAAAACACCAGACAAATGCGATCCTTCCTTA-3’ 
IL-6 5’-AGTAACCACCCCTGACCCAACT-3’ 5’-TGTTGTGTTCTTCAGCCACTCA-3’ 5’-CCTGCTGGCTAAGCTGCATTCACAGA-3’ 
RelA (p65) 5’-GCTTATGGATTCTGAGGGTGTGT-3’ 5’-CCAAAAGGATATAGATACTGCCAATAAA-3’ 5’-CCAACTGCCCCCAACTTCTTTGGG-3’ 
IL-10 5’-CTTGTCGGAGATGATCCAGTTTT-3’ 5’-AGTTCACGTGCTCCTTGATGTCT-3’ 5’-ATGCCCCAGGCTGAGAACCACG-3’ 
Collagen 
type II 
5’-CGCTGTCCTTCGGTGTCA-3’ 5’-CTTGATGTCTCCAGGTTCTCCTT-3’ 5’-TCCGGCAGCCAGGACCGAA-3’ 
Aggrecan 5’-GATGCCACTGCCACAAAACA-3’ 5’-GATGCCACTGCCACAAAACA-3’ 5’-CCGAGGGTGAAGCTCGAGGCAA-3’ 
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Results 
 
siRNA screening and vector development 
 
Six different sequences targeting IL-1β were evaluated for knockdown efficiency in 
chondrocyte monolayer cultures.  All 6 sequences led to significantly decreased expression of 
IL-1β 24 hours following stimulation with LPS (50μg/ml) (Figure 3.1a), however, sequence 
#1 and #2 showed slightly superior silencing.  Both sequences showed efficient IL-1β 
silencing following ligation into the plasmid pSilencer and transfection of cells using Fugene 
HD (Figure 3.1b).  Sequence #1 appeared to have superior silencing compared to #2 (Figure 
3.1b); therefore, sequence #1 was selected as the shRNA to be expressed by the rAAV vector.  
Continued efficient knockdown of IL-1β was observed following ligation of shIL-1β #1 into 
the AAV transfer plasmid that was designed to co-express tdTomato (Figure 3.1c).   
 
Transduction efficiency of rAAV2-tdT-shIL-1β in equine chondrocytes cultured in monolayer 
 
The red fluorescent protein, tdTomato, was packaged into the rAAV2 vector in order 
to assess transduction efficiency.  Equine chondrocytes cultured in monolayer were efficiently 
transduced with the rAAV2-tdT-shIL-1β vector, as determined by flow cytometry quantifying 
expression of tdTomato (Figure 3.2a-c).  The percentage of cells (± SEM) expressing 
tdTomato increased throughout the 72 hour culture period following transduction.  At 24 
hours post-transduction, 16±1.66% of cells were positive; at 48 hours post-transduction, 
31.9±2.0% of cells were positive; and at 72 hours post-transduction 42.2±1.44% of cells were 
 85 
 
positive for the reporter protein (Figure 3.2b,c).  Fluorescence microscopy images taken at 
similar time points supported the flow cytometry findings (Figure 3.3).  The number of cells 
expressing tdTomato increased over the 72 hour culture period.   
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Figure 3.1. Changes in expression of IL-1β in chondrocytes 24 hours following stimulation 
with LPS (50μg/ml).  % Change (±SEM) is shown relative to control chondrocytes treated 
with LPS. (a) Comparison of six different siRNA targeting sequences, all of which show 
significant decrease in IL-1β expression. (b) IL-1β expression in LPS-stimulated 
chondrocytes following transfection with pSilencer expressing shIL-1β #1 and shIL-1β #2. (c) 
IL-1β expression in LPS-stimulated chondrocytes following transfection with the rAAV 
transfer plasmid co-expressing tdTomato.  Different letters denote significant differences 
between groups as determined using ANOVA followed by Tukey’s post-hoc analysis.  p<0.05 
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Figure 3.2.  Chondrocytes cultured in monolayer and transduced with the rAAV2-tdT-shIL-
1β vector. Fluorescence was quantified using flow cytometry and visually assessed using 
fluorescence microscopy.  (a) Representative flow cytometric plot of untransduced 
chondrocytes used to set fluorescent gates to account for autofluorescence of chondrocytes. 
(b) Transduction efficiency assessed by % of chondrocytes (±SEM) expressing the fluorescent 
protein, tdTomato 24, 48 and 72 hours post-transduction.  (c) Representative flow cytometric 
plots of transduced chondrocytes 24, 48 and 72 hours following transduction.  
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Figure 3.3. Representative bright field (top) and fluorescence microscopy (bottom) images of 
chondrocytes cultured in monolayer (a) 24 hours, (b) 48 hours, and (c) 72 hours post-
transduction with rAAV2-tdT- shIL-1β.  Fluorescence intensity and number of cells 
expressing the fluorescent protein increased during the 72 hour culture period. Magnification, 
20x. 
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Effect of rAAV2-tdT-shIL-1β transduction on expression of catabolic cytokines and 
degradative enzymes  
 
Expression of catabolic cytokines and degradative enzymes, including IL-1β, tumor 
necrosis factor-α (TNF-α), MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, was evaluated 
in rAAV2-tdT-shIL-1β transduced and untransduced chondrocyte cultures 24 hours following 
LPS stimulation.  Changes in expression of all genes were evaluated relative to LPS 
stimulated chondrocytes (LPS).  All catabolic cytokines and enzymes were significantly 
increased in LPS cultures compared to cultures that received no LPS stimulation (Figure 3.4).   
IL-1β expression was significantly decreased in shIL-1β+LPS chondrocytes compared to LPS 
chondrocytes, 24 hours following LPS stimulation (p<0.0001) (Figure 3.4a) consistent with 
IL-1β RNA interference.  IL-1β expression was reduced by approximately 42% in shIL-
1β+LPS chondrocytes but remained significantly higher than C and shIL-1β chondrocytes.  
TNF-α expression was also significantly reduced in shIL-1β+LPS chondrocytes compared to 
LPS chondrocytes, 24 hours following LPS stimulation (p=0.017) (Figure 3.4b) as was 
expression of ADAMTS-5 (p=0.0001) (Figure 3.4c). There were no significant differences in 
expression of MMP-3, MMP-13, or ADAMTS-4 in shIL-1β+LPS chondrocytes and LPS 
chondrocytes (Figure 3.4d-f).  
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Figure 3.4. Quantitative polymerase chain reaction (qPCR) data showing % change in gene 
expression of catabolic cytokines and degradative enzymes in control (C), untransduced, LPS 
stimulated (LPS), rAAV2-tdT-shIL-1β transduced (shIL-1β) and rAAV2-tdT-shIL-1β 
transduced, LPS stimulated (shIL-1β+LPS) chondrocytes.  % Change (±SEM) is shown 
relative to LPS chondrocytes. shIL-1β+LPS chondrocytes had significantly decreased (a) IL-
1β, (b) TNF-α and (c) ADAMTS-5 expression compared to LPS chondrocytes. Expression of 
(d) ADAMTS-4, (e) MMP-3 and (f) MMP-13 showed no significant differences between 
shIL-1β+LPS and LPS chondrocytes.  Data were analyzed using ANOVA followed by 
Tukey’s post-hoc analysis. p<0.05 
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Effect of rAAV2-tdT-shIL-1β transduction on expression of pro-inflammatory mediators 
 
In addition to the major catabolic cytokines and degradative enzymes in articular 
cartilage, changes in expression of several inflammatory mediators were evaluated.  
Expression of RelA (p65), a major subunit in the NF-κB family of transcription factors, was 
significantly increased by LPS stimulation in both LPS and shIL-1β+LPS chondrocytes 
compared to unstimulated chondrocytes (Figure 3.5a).  Additionally, RelA (p65) expression 
in shIL-1β+LPS chondrocytes was even higher than in LPS chondrocytes (p=0.005).  IL-6 
expression was significantly increased by LPS stimulation in both untransduced and 
transduced chondrocytes (Figure 3.5b).  Similar to the pattern seen with RelA (p65), IL-6 
expression in shIL-1β+LPS chondrocytes was significantly higher than that of LPS 
chondrocytes (p=0.01). Finally, expression of IL-10 was significantly increased by LPS 
stimulation (Figure 3.5c).  shIL-1β+LPS chondrocytes had the highest expression of IL-10, 
however, this was not significantly different than LPS chondrocytes.   
 
Supernatants from chondrocyte cultures were collected 24 hours following LPS 
stimulation and PGE2 concentrations were quantified using ELISA.  PGE2 was significantly 
increased in LPS stimulated chondrocytes compared to unstimulated chondrocytes.  However, 
PGE2 was significantly decreased in shIL-1β+LPS chondrocytes compared to LPS 
chondrocytes (p=0.029) (Figure 3.6). 
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Figure 3.5. Quantitative polymerase chain reaction (qPCR) data showing % change in gene 
expression of inflammatory mediators in control (C), untransduced, LPS stimulated (LPS), 
rAAV2-tdT-shIL-1β transduced (shIL-1β), and  rAAV2-tdT-shIL-1β transduced, LPS 
stimulated (shIL-1β+LPS) chondrocytes.  % Change (±SEM) is shown relative to LPS 
chondrocytes.  Expression of (a) RelA (p65), (b) IL-6 and (c) IL-10 was significantly 
increased with LPS stimulation.  The expression of both (a) RelA and (b) IL-6 were highest in 
shIL-1β+LPS chondrocytes.  Data were analyzed using ANOVA followed by Tukey’s post-
hoc analysis. p<0.05 
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Figure 3.6. PGE2 concentration in medium collected from chondrocyte cultures 24 hours after 
stimulation with LPS.  Chondrocytes transduced with rAAV2-tdT-shIL-1β had significantly 
decreased PGE2 in the medium compared to LPS chondrocytes. p<0.05 
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Effect of rAAV2-tdT-shIL-1β transduction on expression of anabolic factors  
 
Expression of anabolic factors, including aggrecan and collagen type II, was also 
evaluated in rAAV2-tdT-shIL-1β transduced and untransduced chondrocyte cultures 24 hours 
following LPS stimulation.  Changes in expression of all genes were evaluated relative to LPS 
chondrocytes.  LPS stimulation caused significant suppression of both collagen type II and 
aggrecan expression (Figure 3.7a,b).  Expression of collagen type II was highest in C 
chondrocytes (Figure 3.7a).  Interestingly, collagen type II expression was suppressed in 
shIL-1β chondrocytes that were transduced only (no LPS stimulation) compared to C 
chondrocytes (p<0.0001) (Figure 3.7a).   Additionally, the suppression of collagen type II in 
LPS chondrocytes was not rescued by IL-1β silencing.  A similar pattern was noted in 
expression of aggrecan; shIL-1β chondrocytes had lower aggrecan expression than C 
chondrocytes (p<0.0001) (Figure 7b).  Again, aggrecan suppression seen in LPS 
chondrocytes was not rescued by IL-1β silencing.   
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Figure 3.7. Quantitative polymerase chain reaction (qPCR) data showing % change in gene 
expression of ECM proteins in control (C), untransduced, LPS stimulated (LPS), rAAV2-tdT-
shIL-1β transduced (shIL-1β), and rAAV2-tdT-shIL-1β transduced, LPS stimulated (shIL-
1β+LPS) chondrocytes.  % Change (±SEM) is shown relative to LPS chondrocytes.   
(a) Collagen type II and (b) aggrecan are shown. Both collagen type II and aggrecan 
expression are decreased with LPS stimulation and this is not rescued with rAAV2-tdT-shIL-
1β transduction. Data were analyzed using ANOVA followed by Tukey’s post-hoc analysis. 
p<0.05 
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Discussion 
 
Transduction of equine chondrocytes in monolayer with the rAAV2-tdT-shIL-1β 
vector led to effective post-transcriptional silencing of IL-1β following stimulation with LPS.  
To the authors’ knowledge, this is the first report of knockdown of a pivotal catabolic 
cytokine in the pathogenesis of OA, in equine chondrocytes, using a rAAV vector expressing 
a shRNA targeting IL-1β.  IL-1β interference also had significant downstream effects on a 
major degradative enzyme, ADAMTS-5, and catabolic cytokine, TNF-α.  Additionally, 
supernatants from LPS-stimulated chondrocytes transduced with rAAV2-tdT-shIL-1β had 
significantly less PGE2 than untransduced, LPS-stimulated chondrocytes.  Despite alterations 
in several factors involved in degradation of the ECM and pathogenesis of OA, IL-1β 
interference did not rescue suppression of ECM components, including collagen type II and 
aggrecan, observed following LPS stimulation.   
 
The self-complementary rAAV2-tdT-shIL-1β vector was able to effectively transduce 
chondrocyte cultures.  As expected, transduction efficiency increased over the 72 hour culture 
period, although at 72 hours following transduction, only 42% of cells were tdTomato+.  
Similar studies evaluating rAAV2 mediated transduction of chondrocytes have shown higher 
efficiencies (~96%) 7 days following transduction;
22
 therefore, it is likely that the percentage 
of cells expressing tdTomato would have continued to increase past the 72 hour culture period 
used in this study.  Cells were stimulated with LPS 48 hours post-transduction when 
approximately 30% of cells were positive for expression of tdTomato which may explain the 
only moderate knockdown (~40%) of IL-1β observed.  Chondrocytes have been shown to 
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quickly dedifferentiate when cultured in monolayer;
23
 therefore, it can be difficult to establish 
an ideal culture length in which chondrocytes maintain their phenotype but are also able to 
reach peak transduction.   
 
By targeting IL-1β, a key cytokine in the catabolic cascade, the degradative enzyme 
(ADAMTS-5) and catabolic cytokine (TNF-α) activated by IL-1β were simultaneously 
decreased.  Although both MMPs and aggrecanases are involved in breakdown of the ECM, 
aggrecanases likely play a more dominant role.
24
  Within the aggrecanase family, ADAMTS-
5 has been shown to be the major aggrecanase in murine and equine cartilage 
degeneration.
25,26
 Decreased expression of TNF-α in rAAV2-tdT-shIL-1β transduced 
chondrocytes is also encouraging because, along with IL-1β, TNF-α plays a central role in 
joint inflammation and degradation.
27
  We also found that IL-1β knockdown led to 
significantly less production of PGE2, an inflammatory mediator that contributes to ECM 
breakdown.
28
 Unfortunately, similar decreases in other downstream factors including MMP-3, 
MMP-13 and ADAMTS-4 were not found with IL-1β knockdown.  The differences in 
downstream effects following IL-1β knockdown likely reflects the complex regulatory 
pathways at play.  Although the catabolic cytokines and degradative enzymes evaluated in 
this study are closely related in the OA joint, each gene is individually regulated within the 
cell and different responses to shRNA treatment can be expected. 
 
Although rAAV2-tdT-shIL-1β led to encouraging changes in several important 
mediators of OA, the vector was also associated with a pro-inflammatory response. NF-κB is 
a dimeric transcription complex made of several different proteins and is a central regulator of 
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cellular inflammation.
29
  RelA (p65) is a major subunit involved in NF-κB activation which 
causes upregulation in expression of several proinflammatory cytokines including IFN-γ, 
TNF-α, and IL-6.30  In this study, LPS stimulation led to significant upregulation of RelA 
(p65) expression.  Intriguingly, RelA (p65) expression was even higher in shIL-1β+LPS 
chondrocytes compared to LPS chondrocytes.  A similar pattern was seen for IL-6.  Such 
alterations in these pro-inflammatory genes were not observed in transduced chondrocytes 
that were not stimulated with LPS which suggests a synergistic effect of rAAV2-tdT-shIL-1β 
transduction and LPS stimulation.   Possible explanations for increased expression of RelA 
(p65) and IL-6 include an immune response to AAV or to the shRNA that is produced.  Both 
AAV and shRNA duplexes are capable of activating an intracellular immune response 
through TLR9 or TLR7 signaling, respectively.
31,32
  Additionally, off-target silencing and 
undesirable alterations in gene expression have been shown to be a side effect of shRNA 
treatment.
33
  Evaluation of an AAV vector with a non-targeting shRNA sequence and an AAV 
vector without a shRNA sequence would have provided important information regarding the 
cellular immune response.  Temporal gene expression patterns as well as a more complete 
evaluation of the transcriptome would also shed light on the effects of rAAV2-tdT-shIL-1β 
transduction in equine chondrocytes.  It is important to note that although increases in RelA 
(p65) expression suggest activation of the NF-κB pathway, further evidence including 
phosphorylation of RelA (p54) and nuclear translocation of the complex are needed to 
confirm this.  Detection of phosphorylated RelA (p65) in nuclear extracts can be 
accomplished using Western blot analysis.   
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Knockdown of IL-1β in stimulated chondrocytes failed to rescue the suppression of 
matrix proteins caused by LPS.  Expression of aggrecan and collagen type II, the major 
components of the ECM, was significantly decreased following LPS stimulation and this 
effect was not altered by rAAV2-tdT-shIL-1β transduction.  In fact, transduction alone 
appeared to decrease production of ECM proteins.  It is possible that an intracellular immune 
response to the rAAV vector and/or the shRNA sequence led to these changes; however, 
further experiments are required to elucidate these potential responses.   
 
A major limitation of this study is the lack of an assay to detect IL-1β protein levels 
following IL-1β silencing. Despite evaluation of several commercially available monoclonal 
antibodies against IL-1β, we were unable to find an antibody that would cross-react with 
equine IL-1β at the levels synthesized in these experiments.  Equine IL-1β is a seemingly 
minimally antigenic protein in mice, which limits the ability to develop an equine specific 
monoclonal antibody.  Although changes in gene expression are evident, the results of this 
study would be strengthened by further evidence of ligand synthesis via ELISA or Western 
blot analysis.     
 
In summary, rAAV2-mediated post-transcriptional silencing of IL-1β helps protect 
chondrocytes following stimulation with LPS, a common in vitro model of OA.  Transduction 
of chondrocytes in monolayer with the rAAV2-tdT-shIL-1β vector led to decreased 
expression of IL-1β which in turn downregulated expression of ADAMTS-5 and TNF-α, and 
decreased production of PGE2.  The apparent increase in the inflammatory mediators RelA 
(p65) and IL-6 in rAAV2-tdT-shIL-1β transduced chondrocytes stimulated with LPS 
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compared to untransduced chondrocytes stimulated with LPS is a concern and warrants 
further investigation.  Overall, the results in this study suggest that RNAi may be a feasible 
approach for manipulating the transcriptome in chondrocytes following injury.  
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CHAPTER 4 
 
 
HUMORAL AND CELL-MEDIATED IMMUNE RESPONSE, AND GROWTH FACTOR 
SYNTHESIS, AFTER DIRECT INTRA-ARTICULAR INJECTION OF rAAV2-IGF-I AND 
rAAV5-IGF-I IN THE EQUINE MIDDLE CARPAL JOINT 
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Abstract 
 
Intra-articular (IA) administration of viral vectors expressing a therapeutic transgene is 
an attractive treatment modality for osteoarthritis (OA) as the joint can be treated as a 
contained unit.  Recombinant adeno-associated viruses (rAAV) are useful vectors as they lack 
pathogenicity and have long-term transgene expression.  Although once considered minimally 
immunogenic, concerns regarding the humoral and cell-mediated immune response to AAV 
have been recently expressed. In vivo transduction of articular tissues has been investigated, 
however, the immune response to IA vectors remains largely unknown.  We hypothesized that 
IA rAAV2 and rAAV5 overexpressing insulin-like growth factor-I (IGF-I) would result in 
long-term IGF-I formation but would also induce neutralizing antibody (NAb) and cytotoxic 
CD8+ T-cell responses.  Twelve healthy horses were assigned to treatment (rAAV2 or 
rAAV5) or control (saline) groups.  Middle carpal joints were injected with 5 x 10
11
vg/joint.  
Synovial fluid was analyzed for changes in composition, NAb titers, immunoglobulin 
isotypes, pro-inflammatory cytokines and IGF-I.  Serum was analyzed for antibody titers and 
cytokines.  A T-cell re-stimulation assay was used to assess T-cell responses. Injection of 
rAAV2- or rAAV5-IGF-I did not induce greater inflammation compared to saline.  Synovial 
fluid IGF-I from rAAV5-IGF-I treated joints was significantly increased by day 14 and 
remained elevated until day 56.  IGF-I in rAAV2-IGF-I treated joints was only significantly 
increased on day 56.  A capsid specific T-cell response was not noted although all virus 
treated horses had increased NAb in serum and synovial fluid following treatment.  Overall, 
IA injection of rAAV2- or rAAV5-IGF-I did induce a humoral immune response but did not 
incite a clinically detectable inflammatory or cell-mediated immune response.  The 
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overexpression of anabolic cytokines such as IGF-I using minimally immunogenic viral 
vectors represents a clinically relevant tool for treatment of articular disorders including OA.   
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Introduction 
 
Traumatic joint injury is common, and due to the poor intrinsic healing capabilities of 
cartilage, often precipitates osteoarthritis (OA).
1
  Currently there are no disease-modifying 
treatments for cartilage damage or OA and end-stage arthritic joints often require total joint 
replacement surgery.  Gene therapy approaches to enhance cartilage repair and treat OA have 
great potential as vectors carrying transgenes can be injected intra-articularly for 
concentrated, local therapeutic protein production.  Previous studies have shown that articular 
tissues, including synoviocytes and chondrocytes, can be transduced through direct IA 
injection.
2-4
  Gene therapy techniques, which provide long-term in situ expression of repair-
enhancing genes, would be superior to repeated injections or depots of peptide that are 
transient.  
 
Insulin-like growth factor-I (IGF-I) has been shown to have anabolic and mitogenic 
effects on chondrocytes with increased production of extra-cellular matrix (ECM) proteins 
including collagen type II and aggrecan.
5
  IGF-I has also been shown to enhance the repair 
potential of chondrocytes 
6
 and aids in the protection and recovery of the ECM following 
damage 
7
.  Intra-articular overexpression of IGF-I following cartilage damage could aid in 
chondrocyte-mediated repair of the articular surface thereby limiting joint degeneration and 
OA.  
   
Many different viral vectors including retrovirus,
8
 lentivirus,
9
 and adenovirus 
2
 have 
been investigated for use in OA.  However, a significant impediment has been the substantial 
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immune response which limits transduction and transgene expression 
2
.  Adeno-associated 
virus (AAV) may be a promising alternative as it is non-pathogenic, invades dividing and 
non-dividing cells and has long-term transgene expression.
10
  Many AAV serotypes exist with 
wide tropism that appears to be both tissue and species specific; both AAV2 and AAV5 have 
been shown to effectively transduce equine synoviocytes and chondrocytes in our laboratory 
11
 and by others.
12
 
 
Although AAV has great potential as a viral vector for gene therapy, the immune 
response to capsid proteins has surfaced as a major obstacle to its success.  The humoral 
response has been well-documented and it is estimated that 20-40% of humans have 
neutralizing antibody titers against any given serotype.
13,14
  Prevalence of NAbs depends on 
serotype with 80% of humans having neutralizing antibodies to AAV2.
15
  Several animal 
studies have shown that titers as low as 1:2 - 1:4 can prevent successful transduction.
16-18
  The 
presence of NAbs in synovial fluid has been shown and may limit IA gene transfer.
19,20
  
Although the immune response to AAV appears primarily humoral, a cellular immune 
response to epitopes present on the AAV capsid has been recently elucidated in several 
studies.
21-24
  There is minimal viral gene expression in rAAV, but capsid proteins can be 
presented by MHC I in transduced cells following viral uncoating and processing.
25
  
Cytotoxic CD8
+
 T cells that recognize capsid proteins loaded into MHC I would be able to 
eliminate transduced cells.   
 
In this study, we aimed to investigate both the humoral and T-cell response to IA 
administration of rAAV2 and rAAV5, quantify the production of the therapeutic transgene 
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IGF-I, and correlate the immune response with transgene expression. We hypothesized that 
rAAV2- and rAAV5-IGF-I would lead to minimal joint inflammation following injection and 
would lead to increased levels of IGF-I in the synovial fluid.  However, IGF-I concentrations 
would be limited by the presence of pre-existing neutralizing antibodies.  Additionally, we 
hypothesized that a T-cell response would be invoked by re-stimulation of T cells with the 
AAV serotype to which the horse has been previously exposed.  
 
Materials & Methods  
 
Adeno-associated virus vector preparation 
 
Full-length equine IGF-I cDNA was amplified by PCR.  Equine IGF-I cDNA was 
subcloned into the rAAV transfer plasmid pHpa-trs-SK with SacII and NotI sites.  The 
transgenes were flanked by inverted terminal repeats and under control of the CMV promoter.  
Self-complementary rAAV2-IGF-I and rAAV5-IGF-I vectors were generated by the Research 
Vector Core at The Children’s Hospital of Philadelphia (CHOP) in HEK293 cells using the 
triple plasmid transfection method in which cells were transfected with three different 
plasmids. The plasmids included: 1) rAAV-IGF-I construct, 2) the AAV rep and cap genes 
and 3) the adenovirus helpervirus.  
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Horses 
 
All animal procedures were approved by the Institutional Laboratory Animal Care and 
Use Committee at Cornell University.  Twelve, healthy adult horses (6 geldings, 6 mares) 
between the ages of 5-19 years (median age=12.5 years) were assigned to one of 3 treatment 
groups: 1) Dulbecco’s phosphate-buffered saline (DPBS) injection, 2) rAAV2-IGF-I, or 3) 
rAAV5-IGF-I, with 4 horses per group.  Both middle carpal (MC) joints of each horse were 
used and were randomly assigned to either treatment (viral vector) or saline control.  The 
DPBS injected group had both joints injected with DPBS in order to serve as a viral-free 
control group for evaluation of the systemic response to IA AAV injection.   There were 7 
Thoroughbreds, 1 Quarter Horse and 3 Warmbloods. 
 
Intra-articular injection  
 
Intra-articular injection was performed in horses sedated with xylazine hydrochloride 
(0.4mg/kg IV) and butorphanol (0.01mg/kg IV).  Both MC joints were clipped and prepared 
aseptically, held in flexion and a 21 gauge, 1.5 inch needle was inserted into the dorsolateral 
aspect of the joint.  Synovial fluid was collected from the joint prior to injection of 5 x 10
11
 
viral genomes (vg) in 3ml of sterile DPBS or 3ml of sterile DPBS alone on day 0. 
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Clinical Response to Vector Injection 
 
Prior to injection with the viral vector, horses were evaluated for lameness using the 
AAEP grading system (0-5),
26
 range of motion of the carpi (0-4), joint effusion (0-4) and 
response to sustained joint flexion (0-4).  The circumferences of both MC joints were 
measured using a flexible measuring tape.  Lameness evaluations and joint circumference 
measurements were repeated at days 4, 7, 14, 28, and 56 post-injection.   
 
Synovial fluid analysis 
 
Whole blood from the jugular vein and synovial fluid from the MC joint of both 
forelimbs was collected immediately prior to viral vector injection and then at day 4, 7, 14, 28 
and 56 post-injection.  Cytological analysis of the synovial fluid was performed with total and 
differential leukocyte count performed by Coulter (Beckman Coulter Inc., Fullerton, CA).  
Smear evaluation was performed on Wrights-stained smears (Hema-Tek, Siemens, Germany).   
Synovial fluid was analyzed for IGF-1 concentration using ELISA (Quantikine, R&D 
Systems, Minneapolis, MN).  Synovial fluid was also analyzed for cytokine production by 
fluorescent bead-based multiplex assays (IL-10, IFN-γ, IFN-α, sCD14, and CCL2).27,28 
 
Synovial biopsy 
 
Synovial tissue was collected from the dorsal joint pouch 56 days post-injection.  
Biopsies were performed with horses standing and sedated with detomidine (0.02mg/kg IV) 
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and butorphanol (0.01mg/kg IV).  Following sterile preparation of the dorsal aspect of the MC 
joint, a scalpel was used to incise the skin and joint capsule and Ferris-Smith rongeurs were 
used to collect synovium.   Samples were fixed in 4% paraformaldehyde or placed in a -80
o
C 
freezer for RNA extraction.  Synovial membrane was sectioned, stained with hematoxylin and 
eosin (H&E), and scored using a semi-quantitative scoring system. 
 
IGF-I Gene expression analysis 
 
Following pulverization using a mortar and pestle, tissues were mechanically 
homogenized using a battery operated pestle grinder and vortex, and then RNA was isolated 
from tissues using the PerfectPure RNA Tissue Kit (5 Prime, Gaithersburg, MD).  Purity and 
concentration of the RNA was assessed by UV microspectrophotometry (NanoDrop 2000 
Spectrophotometer, Thermo Scientific, Waltham, MA).  Gene expression was quantified by 
real-time PCR using the Taqman One-Step RT-PCR technique (Absolute Quantitative PCR; 
ABI PRISM 7900 HT Sequence Detection System, Applied Biosystems, Foster City, CA).  
Primer Express Software Version 2.0 (Applied Biosystems, Foster City, CA) was used to 
design equine primers and dual-labeled fluorescent probes [6-carboxyfluorescein (FAM) as 
the 5’ label (reporter dye) and 5-carboxymethylrhodamine (TAMRA) as the 3’ label 
(quenching dye)].  Sequences for primers and probes were generated from GenBank (National 
Institutes of Health, Bethesda, MD).  Primer sequences for 18S used as a housekeeping gene 
were as follows: forward, 5’-CGGCTTTGGTGACTCT AGATAACC-3’ and reverse, 5’-
CCATGG TAGGCACAGCGACTA-3’ and for IGF-I were as follows: forward, 5’-
TGTACTGCGCACCCCTCAA-3’ and reverse, 5’-TTGTGTTCTTCAAATGTACTTCCTTC 
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TG-3.  Gene expression of IGF-I was measured in duplicate for all samples.  The total copy 
number of mRNA was determined using a validated standard curve and these values were 
normalized 18S.   
 
In vitro transduction inhibition assay 
 
Serum and synovial fluid samples collected at days 0, 28 and 56 were heat inactivated 
and analyzed by an in vitro neutralizing antibody assay 
13
.  Recombinant rAAV-LacZ 
(10
9
vg/well) was diluted in serum-free DMEM and incubated with 2-fold serial dilutions 
(initial dilution, 1:5) of samples for 1 hour at 37
o
C.  The mixture was added to 96-well plates 
seeded with 1 x 10
5
 Huh7 cells/well infected 2 hours prior with WT HAdV5 (50 viral 
particles/cell).  Wells were incubated for 18-22 hours.  Cells were then washed and lysed, and 
lysate developed with β-galactosidase assay kit for bioluminescence (Applied Biosystems, 
Foster City, CA).  Neutralizing antibody titers were reported as highest sample dilution that 
inhibited rAAV-LacZ transduction (β-gal expression) by ≥50%, compared with mouse serum 
control. 
 
Immunoglobulin isotyping 
 
Immunoglobulin isotyping assays were performed as previously described with some 
modifications .
29,30
  Enzyme-linked immunosorbent assay (ELISA) plates (Costar, Corning 
Inc., Corning, NY) were coated with rAAV2 or rAAV5 virions at 1μg/ml and incubated at 
4
o
C overnight.  Plates were then incubated with blocking buffer (4% BSA/PBS) for 1 hour.  
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Plates were washed five times between all subsequent steps.  Equine serum or synovial fluid 
samples were diluted 1:100 and incubated for 1 hour at 37
o
C.  Serum and synovial fluid 
samples with known high antibody titers from previous testing were serially diluted and used 
to establish a standard curve.  The highest dilution was assigned an ELISA unit of 200 or 400 
depending on the isotype being tested.  Serum and synovial fluid samples with known 
negative titers were used as a negative reference sample.  Plates were incubated for 1 hour 
with primary monoclonal antibodies including IgG1 (1:10), IgG4 (1:20), IgG5 (1:10), and 
IgM (1:20) (Table 4.1).  A secondary peroxidase-conjugated anti-mouse IgG (H+L) antibody 
(Jackson ImmunoResearch, West Grove, PA) at 1:200,000 was added followed by tetramethyl 
benzidine substrate for chromagen development. Optical density was measured using a Tecan 
plate reader for absorbance at 450 nm. 
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Table 4.1. Primary monoclonal antibodies used for immunoglobulin isotyping 
 
Antibody Ig Subtype recognized 
1-22 IgM 
CVS 45 IgG1 (IgGa) 
CVS 39 IgG4 (IgGb) 
416-2 IgG5 (IgG(T)) 
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T-cell intracellular cytokine assay 
 
Whole blood was collected from horses 7 days prior to virus injection and at days 14 
and 56 post-injection.  Peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation (Ficoll-Paque Plus; GE Healthcare, Piscataway, NJ).  PBMCs (3 x 
10
6
) were cultured in 24-well plates in 1000μL of cell culture medium (Dulbecco’s modified 
Eagles’ medium [DMEM], 10% [vol/vol] fetal calf serum, 1% [vol/vol] nonessential amino 
acids, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, 50 μg/ml gentamicin; all from Gibco, 
Invitrogen, Grand Island, NY).  Stimulated cells were treated with phorbol myristate acetate 
(PMA)-ionomycin (Sigma, St. Louis, MO) as a positive control for T-cell activation, or with 
rAAV serotype 2 or 5.  Non-stimulated cells were cultured in medium only.  At 24 hours of 
culture, Brefeldin A (Sigma, St. Louis, MO) was added to all wells to inhibit cytokine 
excretion in preparation for intracellular cytokine staining.  Following 48 hours of culture, 
cells were fixed, permeabilized, and stained for CD4 or CD8 and for IFN-γ expression by 
using directly labeled antibodies and isotype-matched controls as previously described 
31
.  A 
FACSCanto II flow cytometer (BD Biosciences, San Diego, CA) was used to analyze cells 
with fluorescence gates set according to isotype control staining.   
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PBMC cytokine secretion assay 
 
PBMCs (6 x 10
5
) were cultured in 96-well plates in 200 μl of culture medium as 
described above.  Stimulated cells were treated with PMA-ionomycin or with rAAV serotype 
2 or 5.  Non-stimulated cells were cultured in medium only.  Following 48 hours of culture at 
37
o
C supernatants were collected and analyzed for IL-10, IFN-γ, and IFN-α concentration 
using a fluorescent bead-based multiplex assay 
27
.  IL-6 concentrations were quantified using 
ELISA 
32
.   
 
Statistics  
 
A Kruskal-Wallis test was used to compare differences between groups.  A mixed 
effects model, with horse as a random effect, was constructed and least squared means was 
used to compare changes in synovial fluid composition and IGF-I concentration over time.   
Day was treated as a categorical variable to allow for the non-linear effect of time.  Multiple 
comparisons for each interaction were made with a Tukey’s post hoc test.  Specific linear 
contrasts were fitted to the model where appropriate.  A mixed effects model was also 
performed for analysis of associations between NAb titers, immunoglobulins, and IGF-I 
concentrations.  Statistical analysis was performed using JMP. The level of significance was 
set at p<0.05. 
 
 
 125 
 
Results 
 
Joint response to vector injection 
 
Injection of rAAV2-IGF-I or rAAV5-IGF-I did not induce greater articular 
inflammation compared to DPBS injected control joints at any time point.  Lameness grades, 
% change in joint circumference, joint effusion, range of motion and response to sustained 
flexion were not different among any of the treatment groups at any time point (Figure 
4.1a,b).  Synovial total protein (TP) levels were slightly increased over baseline in rAAV5-
IGF-I treated joints at days 14 (3.25 ± 0.44g/dl) and 28 (3.25 ± 0.72g/dl), however, these 
increases were not significant and returned to baseline by day 56 (Figure 4.1c).  Total protein 
did not increase in rAAV2-IGF-I treated joints (Figure 4.1c).  Synovial fluid total nucleated 
cell count (NCC) was significantly increased in rAAV5-IGF-I treated joints on day 14 (3375 
± 957.73 cells/μL; p<0.0001) only (Figure 4.1d).  NCC in rAAV5-IGF-I treated joints 
decreased following this time point and were not significantly different than baseline on day 
28 or 56 (Figure 4.1d).  Differential cell counts revealed a trend in both rAAV2- and rAAV5-
IGF-I treated joints, where the % of small mononuclear cells and polymorphonuclear cells 
(PMNs) decreased at day 4 and 7, while % of large mononuclear cells increased.    
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Figure 4.1. Joint response to middle carpal joint intra-articular administration of rAAV2-IGF-
I, rAAV5-IGF-I, or saline. (a) % change in joint circumference, (b) lameness grade, (c) total 
protein concentration and (d) total nucleated cell count. Graphs illustrate mean values ± SEM 
averaged from 4 horses.  * p < 0.05  
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IGF-I synthesis and gene expression 
 
IGF-I synthesis was quantified over time by measuring concentrations in the synovial 
fluid using ELISA. IGF-I concentrations in the synovial fluid from middle carpal joints of 
horses treated with rAAV5-IGF-I were significantly increased over joints treated with saline 
at days 14, 28 and 56 (Figure 4.2a).  Synovial fluid IGF-I concentrations in rAAV2-IGF-I 
treated joints were significantly increased over saline treated joints at day 56 only.  
Additionally, synovial fluid IGF-I content from MC joints treated with rAAV5-IGF-I was 
significantly higher than rAAV2-IGF-I treated joints at days 14 and 28.   
 
IGF-I gene expression in synovial membrane tissue collected at 56 days post-injection 
was quantified using qPCR.  IGF-I mRNA expression was 25 times higher in synovial 
membrane tissue from joints treated with rAAV5-IGF-I and 10 times higher in synovial 
membrane tissue from joints treated with rAAV2-IGF-I, compared to joints treated with saline 
(Figure 4.2b).  IGF-I expression in the synovial membrane from rAAV5-IGF-I treated joints 
was significantly increased over saline treatment (p=0.03) at 56 days post-transduction.  
Overall, IGF-I mRNA expression and synthesis was higher in rAAV5-IGF-I treated joints 
compared to rAAV2-IGF-I treated joints.   
 
AAV2 and AAV5 capsid-specific CD4
+
and CD8
+
 T-cell response 
 
PBMCs were isolated from saline, rAAV2-IGF-I, and rAAV5-IGF-I injected horses at 
days -7 (prior to viral exposure), 14 and 56.  T-cell responses in all 3 groups were assessed in 
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PBMCs re-stimulated with rAAV2 and rAAV5.  Stimulated cells were stained with CD4, 
CD8, and IFN-γ antibodies and flow cytometry analyses were performed (Figure 4.3).  After 
re-stimulation of PBMCs with rAAV2 or rAAV5, horses treated with either virus did not have 
increased IFN-γ+ lymphocytes in either CD4+ or CD8+ populations indicating a lack of a 
cellular immune response (Figure 4.4).  Supernatants collected from rAAV2 or rAAV5 
stimulated PBMCs were also analyzed for production of IL-10, IFN-γ, IFN-α, and IL-6 and 
production characteristic of T-cell activation, viral infection or inflammation.  Stimulation of 
cells from all 3 treatment groups, including saline and both AAV serotypes, did not induce 
significant amounts of IFN-γ (Figure 4.5), which correlates with the results obtained by flow 
cytometry analysis. Additionally, there were no significant changes in IL-10, IFN-α or IL-6 in 
any of the treatment groups.  
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Figure 4.2. (a) IGF-I concentration (ng/ml) in synovial fluid over time in joints injected with 
either rAAV2-IGF-I, rAAV5-IGF-I, or saline.   Graphs illustrate mean values ± SEM 
averaged from 4 horses per group.  * rAAV5 injected horses significantly increased over 
rAAV2 and saline injected horses, p < 0.05. ** rAAV5 and rAAV2 injected horses both 
significantly increased over saline injected horses, p < 0.05.  (b) IGF-I mRNA expression in 
synovium 56 days after intra-articular injection of either rAAV2-IGF-I, rAAV5-IGF-I, or 
saline. * p < 0.05 
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Figure 4.3. Representative flow cytometric plots of lymphocytes following T-cell re-
stimulation assay with AAV2 or AAV5. PBMCs isolated from horses injected with saline, 
rAAV2-IGF-I, or rAAV5-IGF-I were collected at day 0 (prior to viral exposure), day 14, and 
day 56.  Following re-stimulation, cells were stained for CD4, CD8 and intracellular IFN-γ.  
An isotype control was used to establish the quadrant gates for IFN-γ. (a) AAV2 re-stimulated 
PBMCs from rAAV2-IGF-I injected horses and (b) AAV5 re-stimulated PBMCs from 
rAAV5-IGF-I injected horses. 
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Figure 4.4. Total percentages of IFN-γ producing T cells from horses injected with DPBS, 
rAAV2-IGF-I, or rAAV5-IGF-I and re-stimulated with either rAAV2 or rAAV5 at day 14 and 
day 56.   
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Figure 4.5. IFN-γ secretion (pg/ml) measured in the supernatants of rAAV2 or rAAV5 re-
stimulated PBMCs of the 3 treatment groups at days 14 and 56.  
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Neutralizing antibody titers 
 
Neutralizing antibody titers are shown in Figure 4.6.  AAV2 NAb titers in serum and 
synovial fluid were measured in saline injected and rAAV2 injected horses, while AAV5 
NAb titers in serum and synovial fluid were measured in saline injected and rAAV5 injected 
horses.  All tested horses had pre-existing NAb titers to AAV5 in serum and 5/8 horses had 
NAb titers in synovial fluid.  This is in contrast to AAV2 in which no tested horses had pre-
existing NAb titers in either serum or synovial fluid.  The NAb response at day 28 and 56 was 
more robust to AAV5 than AAV2 in both serum and synovial fluid (Figure 4.6a-d).  AAV5 
NAb titers were significantly increased in the serum at day 28 (p=0.03) and day 56 (p=0.03), 
and in the synovial fluid at day 28 (p=0.03) and day 56 (p=0.03) when compared to day 0 
(Figure 4.6a,b).  AAV2 NAb titers were only significantly increased in the serum at day 28 
(p=0.02) and day 56 (0.02) (Figure 4.6c).  The NAb titers in the contralateral saline injected 
joint in the rAAV5 treatment group were also increased at day 28 and 56.  Contralateral joint 
titers were less than rAAV5 injected joint titers, however, there was a significant correlation 
between titers in the virally injected and saline injected joints (r
2
 = 0.74; p=0.003).  There was 
a significant correlation between serum and synovial fluid AAV5 NAb titers (r
2
 = 0.54, 
p=0.007), however, there was not a significant correlation between serum and synovial fluid 
AAV2 NAb titers.   
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Figure 4.6. Reciprocal neutralizing antibody titers to AAV2 in serum (a) and synovial fluid 
(b) (n=4), and to AAV5 in serum (c) and synovial fluid (d) (n=4), from horses prior to 
exposure (day 0) and following IA rAAV2 or rAAV5 injection.  A titer ≥ 1:5 was considered 
positive. * p < 0.05
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Immunoglobulin isotypes 
 
Prior to rAAV injection, 11/12 horses had detectable IgM against AAV2 in their 
serum while 10/12 horses had detectable IgM against AAV5 (Figure 4.7). All horses had 
detectable IgG5 to both AAV2 and AAV5 while 6/12 horses had detectable IgG4 to both 
serotypes.  AAV2-specific IgM increased in the serum of horses injected with rAAV2-IGF-I 
at days 28 and 56 but these increases were not significant compared to the other treatment 
groups (Fig 4.8a).  The synovial fluid IgM concentration had a trend towards increased 
concentrations in rAAV2-IGF-I injected horses at day 56 compared to saline and rAAV5-
IGF-I injected horses (p=0.06).  The synovial fluid IgG1 concentration was significantly 
increased in rAAV2-IGF-I injected horses at days 28 (p=0.0041) and 56 (p=0.0054) compared 
to saline and rAAV5-IGF-I injected horses (Figure 4.8b).  The humoral response to AAV5 
appeared to be more diverse as there were greater changes in immunogloblulin isotypes over 
time in the AAV5-specific ELISA compared to the AAV2-specific ELISA.  AAV5-specific 
IgM was significantly increased in the serum of rAAV5-IGF-I treated horses at day 28 
(p=0.0154) compared to the other treatment groups whereas AAV5-specific IgG1 was 
significantly increased at days 28 (p=0.0092) and 56 (p=0.0054) (Figure 4.8c). In the 
synovial fluid, IgM was significantly increased in rAAV5 treated horses at days 28 
(p=0.0054) and 56 (p=0.05), IgG1 was significantly increased at days 28 (p=0.0054) and 56 
(p=0.0092), and IgG4 was significantly increased at day 56 (p=0.0261) (Figure 4.8d).  The 
amount of AAV2- or AAV5-specific IgG4 or IgG5 in the serum did not change significantly 
over time in any of the 3 treatment groups.   
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Figure 4.7. Pre-existing immunoglobulin isotypes to AAV2 and AAV5 in the serum of horses 
(n=12). 
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Figure 4.8. Immunoglobulin isotype ELISA results from saline, rAAV2, or rAAV5 injected 
horses.  (a) rAAV2-specific isotypes in serum and (b) synovial fluid.  (c) rAAV5-specific 
isotypes in serum and (d) synovial fluid. * p < 0.05; ** p < 0.01 
 142 
 
 
 143 
 
Serum and synovial fluid cytokine and chemokine concentrations 
 
Serum collected from the 3 treatment groups was analyzed for IL-10, IFN- γ, IFN-α, 
sCD14, and CCL2 over time.  There were no significant differences in IFN-γ, IFN-α, IL-10, 
or CCL2 concentrations in serum between the groups at any time point.  Interestingly, the 
effect of day on sCD14 concentrations (p=0.001) but not treatment group was significant in 
the mixed effects model.  sCD14 concentrations at day 28 (mean±SEM; 14452.6±803.8pg/ml) 
and day 56 (14495.9±762.7pg/ml) were significantly higher than sCD14 concentrations at day 
0 (11982.9±942.5pg/ml), day 4 (12185.0±1036.0pg/ml) and day 7 (12455.4±617.6pg/ml).  
There was no detectable IL-10 or IFN-α in the synovial fluid of any horse at any time point.  
There were no significant differences in the amounts of IFN-γ, CCL2 or sCD14 in the 
synovial fluid between any of the treatment groups at any time point.   
 
 
Synovial membrane histology  
 
Synovial membrane biopsies collected from MC joints 56 days post-injection did not 
have significantly different scores between the treatment groups suggesting that direct 
injection of rAAV2 or rAAV5 does not cause a detectable inflammatory response in the 
synovial membrane as indicated by clubbing of villi, subintimal thickening, fibrosis, or 
inflammatory cell infiltration (Figure 4.9).   
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Figure 4.9. Photomicrographs of synovial membrane harvested from middle carpal joints 56 
days following injection of (a) DPBS, (b) rAAV5-IGF-I, or (c) rAAV2-IGF-I.  There were no 
significant differences in histological scores of synovial membrane biopsies obtained from the 
3 treatment groups (d).  Data in table presented as median (range) from 4 horses per group.  
Results analyzed using ANOVA.  
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Correlation between humoral response and IGF-I concentrations in synovial fluid 
 
Interestingly, in rAAV5 treated horses there was a significant positive correlation 
between IGF-I concentration and AAV5 NAb titers in the synovial fluid (r
2
 = 0.52, p=0.04), 
suggesting that horses with higher synovial fluid NAb titers had higher transgene expression 
(Figure 4.10).  No such relationship existed for rAAV2 treated horses.  There were also no 
significant correlations between any specific immunoglobulin isotype in the serum or synovial 
fluid, and IGF-I expression in rAAV2- or rAAV5-IGF-I treated joints.   
 
There was a significant positive correlation between AAV5 NAb titers in the serum 
and IgG1 in rAAV5 treated horses (r
2
 = 0.95; p<0.001).  No other significant correlations 
between AAV5 NAb serum or synovial fluid titers and immunoglobulin isotypes were 
observed.  There was a weak correlation between AAV2 NAb titers in the serum and IgM in 
rAAV2 treated horses (r
2
 = 0.34; p=0.0394).  No other correlations between NAb titers and 
immunoglobulin isotypes were observed in rAAV2 treated horses.   
 
Overall, rAAV5 incited a more diverse and robust humoral response compared to 
rAAV2 following IA injection.  However, IGF-I concentrations in the synovial fluid and 
mRNA expression in the synovial tissue harvested at day 56 following rAAV5 injection were 
higher than in the rAAV2 treated joints.   
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Figure 4.10. Relationship between synovial fluid IGF-I concentration and synovial fluid 
AAV5 NAb titers in horses injected with rAAV5-IGF-I. There was a significant, positive 
correlation between synovial fluid IGF-I concentration and NAb titer.   
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Discussion 
 
rAAV2-IGF-I and rAAV5-IGF-I vectors administered intra-articularly to the middle 
carpal joints of horses were able to effectively transduce articular tissues with expression of 
the therapeutic transgene, IGF-I, throughout the 8 week study period.  Importantly, injection 
of either vector did not cause any significant local inflammation as there were no changes in 
joint effusion, lameness scores, synovial membrane architecture, or synovial fluid nucleated 
cell counts and total protein concentrations.  Although both serotypes successfully transduced 
host tissues, rAAV5-IGF-I showed superior transgene expression with higher synovial fluid 
concentrations of IGF-I and increased gene expression of IGF-I in the synovial tissue.  This 
was in spite of all horses having pre-existing NAb titers to AAV5 and a more robust humoral 
immune response to rAAV5 than rAAV2, following injection.  Transgene persistence was 
evident up to 56 days, with rAAV5-IGF-I expression peaking at 28 days and rAAV2-IGF-I 
peaking at 56 days.  Synoviocytes are the predominant cell type transduced following IA 
injection as chondrocytes are largely sequestered in a thick extra-cellular matrix.
33,34
  
Although synoviocytes appear to be easily transduced, the half-life of these cells is less than 1 
month
34
 which can limit longevity of transgene expression in joints.  Intra-articular transgene 
expression at 56 days suggests transduction of longer lasting cell types such as chondrocytes 
or fibroblasts in the joint capsule and supporting ligaments, as seen in murine joints injected 
with AAV.
35
 
 
Initially, AAV vectors were deemed non-immunogenic based on early murine 
models.
36,37
  Evidence of humoral and cell-mediated immune responses began to emerge as 
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different serotypes, hosts, and transgenes were investigated.  Although the immune response 
to AAV appears to be significantly less than other vectors, such as Adenovirus, several 
studies have shown reduced transduction efficiency and longevity of transgene expression in 
animals with AAV titers as low as 1:4.
16,38
  Few studies have evaluated the immune response, 
and its impact on transgene expression, following direct IA injection of AAV vectors.  In 
order to further elucidate the immune response to IA AAV administration, we investigated the 
humoral and T-cell response in horses injected with rAAV2 or rAAV5 vectors.   
 
Prior to treatment with either AAV serotype, all horses had low NAb titers to AAV5 
while no horses had NAb titers to AAV2.  The majority of horses had pre-existing detectable 
levels of rAAV2-specific IgM (92%) and AAV5-specific IgM (83%).  One horse was IgM 
seronegative for both rAAV2 and rAAV5.  All horses had pre-existing rAAV2- and rAAV5-
specific IgG5.  Pre-existing IgG4 against rAAV2 and rAAV5 was found in the 50% of horses; 
the same 6 horses were seropositive for both serotypes.  Overall, there was a more diverse 
humoral response to rAAV5 injection than to rAAV2 with horses having significant increases 
in serum IgM and IgG1 levels and synovial fluid IgM, IgG1 and IgG4 levels.  IgM showed an 
earlier peak at 28 days followed by decreasing levels at 56 days, while both IgG1 and IgG4 
levels increased from day 28 to 56.  The humoral response to rAAV2 appeared weaker with a 
small increase in serum IgM noted at day 28 and a significant increase in synovial fluid IgG1 
at day 28 and 56.  Although horses had no AAV2 NAb titers at day 0, detectable anti-AAV2 
IgM, IgG4 and IgG5 were present in serum.   This may be explained in part by the differing 
effector functions of immunoglobulin isotypes.  For example, IgM is a strong activator of 
complement but has weak neutralizing abilities whereas neutralization is a major effector 
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function of most equine IgG subclasses, especially IgG1 and IgG4/7.  In our study we also 
saw a strong correlation between AAV5 NAb titers in the serum and IgG1 in rAAV5 treated 
horses, which suggests that IgG1 may play a major role in neutralizing AAV.  Interestingly, 
Chirmule et al. (1999)
39
 also showed that 68% of AAV2-specific antibodies in humans were  
not neutralizing.    
 
The humoral response to rAAV2 and rAAV5 in this group of horses was quite 
variable, with some horses being stronger responders than others. Several investigators have 
shown that the immunoglobulin subclass responses in humans are also widely variable with 
IgG1 responses being most prevalent but IgG2, IgG3 and IgG4 antibodies also being detected 
in most subjects.
40,41
  It should be noted that the human and equine IgG nomenclature does not 
match and that isotypes with the same name are not necessarily functionally identical. 
However, in this study, equine IgG1 responses were also the most prevalent.  Cross-reactivity 
of AAV antibodies has been shown to occur at low levels between some AAV serotypes,
42
 
however, in this study we did not see any significant cross-reactivity between the 2 serotypes 
used.  From this study it is not possible to determine why horses had pre-existing antibodies 
to AAV2 and AAV5; two serotypes isolated from humans.  It is possible that there is cross-
reactivity with similar antigens that horses encounter naturally or that AAV has broad species 
tropism and can infect horses thereby stimulating a humoral response.   
 
Despite the presence of pre-existing NAbs in all rAAV5 injected horses and the more 
robust humoral immune response to this serotype, probably due to an anamnestic response, 
rAAV5 appeared to be a more effective IA vector with higher levels of the transgene being 
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expressed throughout the study period.  IGF-I concentration in the synovial fluid of rAAV5-
IGF-I treated joints peaked at day 28, with a sharp decline noted at day 56.  This may suggest 
loss of transduced cells due to an activated humoral immune system.  Indeed, there were 
higher NAb titers in the rAAV5 injected joint compared to the contralateral saline injected 
joint which could support recruitment of NAbs to the transduced joint.  Alternatively, 
induction of transgene specific CD8
+
 T-cells could have decreased IGF-I expression, although 
this response was not examined in this study. 
 
To the author’s knowledge, no studies have examined the cell-mediated immune 
response to AAV in the horse.  The horse serves as an important large animal model for 
human disease, especially diseases involving the joint.  A greater understanding of the cell-
mediated response is vital to development of clinically relevant AAV vectors for both equine 
and human patients.  This study used several tools, including IFN-γ fluorescent bead-based 
assay and flow cytometry, to further elucidate the T-cell response to 2 commonly used AAV 
serotypes. Based on flow cytometry analysis of IFN-γ+ T cells, re-stimulation of PBMCs with 
either serotype did not elicit an AAV-specific T-cell response.  These findings were supported 
by lack of IFN-γ in the supernatants of re-stimulated cells.  Memory CD8+ T-cell responses 
have been shown in humans,
18,21
 although these responses are seemingly variable and dose-
dependent.  It is hypothesized that, following transduction and viral uncoating, some capsid 
remains in the cytosol and is processed by the proteasome prior to presentation on MHC I 
molecules.  AAV capsid presentation by MHC I results in activation and expansion of capsid-
specific CD8
+
 memory T-cells with subsequent removal of transduced cells. CD4
+
 T-cell 
responses to AAV seem to be less common in humans, possibly due to the poor transduction 
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efficiency of antigen presenting cells (APCs) by AAV.
43
  The lack of AAV-specific CD8+ T-
cells in this study may indicate that horses do not mount a significant cell-mediated response 
to AAV vectors.  However, T-cell responses may have been limited due to the relatively small 
dose of vector (5 x 10
11
vg/joint) and the IA nature of vector administration.  The presence of 
rAAV2- and rAAV5-specific IgM responses and lack of CD8+ T-cell response, could suggest 
that AAV is acting as a T-cell independent antigen in the horse.  Conversely, the 
immunoglobulin class-switching evident in many horses to various AAV-specific IgG 
isotypes is suggestive of a B-cell response that requires CD4+ T-cell help.   
 
Supernatants from re-stimulated PBMCs, serum and synovial fluid were evaluated for 
changes in pro-inflammatory cytokines (IFN-γ, IFN-α, IL-6, IL-10).  Both type I (IFN-α, IFN-
β) and II interferons (IFN-γ) have been shown to increase in mice treated with AAV vectors; 
increases in IFN-α may be up-regulated by AAV following activation of TLR9 in response to 
intracellular viral genomes, while increases in IFN-γ appear to be associated with activated T-
cells.
44
  In this study, there was no evidence of an IFN-α or IFN-γ response in re-stimulated 
PBMCs, serum or synovial fluid at any time point.  Additionally, no significant increases in 
IL-6 or IL-10 were seen following rAAV2 or rAAV5 administration.  IL-10 has been shown 
to increase in human patients following administration of rAAV2,
41,45
 while IL-6 transiently 
increased in mice following systemic injection of AAV.
44
  The lack of significant changes in 
several pro-inflammatory and anti-inflammatory cytokines in these horses is encouraging, as 
it provides further evidence that these viral vectors are not inducing a significant innate or 
cell-mediated immune response.   
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Although serum or synovial fluid immunoglobulin concentrations did not limit 
transgene expression in this group of horses, it is possible that the humoral response observed 
following injection would limit effectiveness of re-administration of the vector, as a large 
dose of virus would again be presented to the primed adaptive immune system.  Cottard et al. 
(2004)
46
 demonstrated that the IgG antibodies in the synovial fluid are primarily responsible 
for limiting transduction efficiency; therefore, increased IgG concentrations following the 
primary AAV exposure could greatly complicate vector re-administration.  If re-
administration is required, a heterologous prime-boost strategy in which serologically distinct 
AAV serotypes are used will be crucial for successful treatment. 
 
Limitations of this study include the small sample size in each treatment group 
especially given the variability in the humoral response observed.  Increasing the number of 
horses per group would allow greater detection of differences.  Additionally, it would have 
been more ideal to continue the study past 56 days given that IGF-I concentrations in the 
rAAV2-IGF-I administered joints peaked at day 56.  A longer term study would allow a more 
comprehensive understanding of transgene expression and persistence by this serotype.  
Finally, re-administration of the vector would have shed light on the in vivo memory immune 
response and potential consequences of increasing AAV-specific IgG antibodies on 
transduction efficiency.   
 
In conclusion, direct IA injection of rAAV2-IGF-I or rAAV5-IGF-I into the middle 
carpal joints of horses led to sustained, high transgene expression without significant local 
inflammation as determined through clinical parameters, synovial fluid composition and 
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synovial membrane histology.  An AAV-specific T-cell response was not detectable in horses 
exposed to either serotype.  Presence of pre-existing NAb to AAV5 did not appear to affect in 
vivo transduction and transgene expression.  A humoral immune response was noted, 
especially in rAAV5 treated horses, although higher NAb titers in synovial fluid were actually 
correlated with increased IGF-I concentrations. This phenomenon could be indicative of a 
more robust tropism of rAAV5 for carpal joints compared to rAAV2, which would allow 
rAAV2 to leak out of the joint cavity and as a consequence minimize the local immune 
response and reduce the levels of IGF-I .  Although, a significant cell-mediated response was 
not observed following IA injection in this group of horses, caution is needed when 
translating this information to human IA gene therapy as there appears to be significant 
differences in the nature of the immune response between species.   Novel techniques such as 
capsid engineering and error-prone PCR to limit epitope presentation may represent feasible 
approaches to improving evasion of host immune responses.
47-49
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CHAPTER 5 
DISCUSSION 
 
The overall goal of this dissertation research was to investigate AAV-mediated dual-
axis gene therapy to improve cartilage repair and prevent osteoarthritis (OA).  The first aim 
evaluated healing of full-thickness chondral defects implanted with autologous chondrocytes 
overexpressing the anabolic protein, IGF-I.  Our second aim was to silence the catabolic 
cytokine, IL-1β, using a rAAV vector expressing a short hairpin RNA sequence, in 
chondrocytes cultured in an OA model.  Due to the humoral immune response to AAV5 noted 
in the first aim, our third aim sought to investigate the humoral and cell-mediated immune 
response to direct intra-articular injection of rAAV2-IGF-I and rAAV5-IGF-I,  and to 
evaluate the impact these responses had on expression of the transgene, IGF-I.   
 
Improved healing in critically-sized (15mm diameter), full-thickness chondral defects 
was seen following implantation of autologous chondrocytes transduced ex vivo with an 
rAAV5-IGF-I vector compared to defects implanted with naïve chondrocytes or a cell-free 
fibrin graft.  rAAV5-IGF-I repaired defects had better semi-quantitative healing scores at 8 
weeks when second-look arthroscopy was performed.  Improved healing scores persisted at 8 
months post-implantation, when necropsy examination was performed.  rAAV5-IGF-I 
implanted defects also had improved histologic appearance and increased collagen type II 
content at this time, which is encouraging as collagen type II is one of principal ECM 
components of hyaline cartilage and provides significant tensile strength to the articular 
surface. 
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The above results suggest that AAV-mediated overexpression of IGF-I improves 
healing capabilities of chondrocytes in the long-term.  However, complete regeneration of 
native hyaline cartilage was not achieved and peripheral integration was not complete.  
Chondrocyte implantation and gene therapy has led to significant improvements in cartilage 
repair but repair tissue continues to be a mixture of fibrocartilage and hyaline cartilage, or 
“hyaline-like”.  When compared to native cartilage, repair tissue generally contains less 
collagen type II that is often disorganized, less proteoglycans indicative of a weaker ECM, 
and lack of complete peripheral integration.  Taken together these shortcomings may indicate 
lack of durability and strength of repair tissue.  It is possible that implanted chondrocytes are 
not surviving long enough in the graft to allow for reformation of hyaline cartilage.  
Chondrocyte survival could possibly be prolonged by overexpression of anti-apoptotic factors 
such as B-cell lymphoma (Bcl)-2 or through control of the catabolic cascade, which leads to 
NF-κB activation and possible cell death. 
 
Activation of the catabolic cascade following injury to articular cartilage and during 
periods of homeostatic stress in chondrocytes (i.e., during culture and implantation) likely 
presents a significant barrier to cartilage repair, which cannot be solely overcome by 
overexpression of an anabolic protein.  IL-1β is a key catabolic cytokine associated with 
degradation of the ECM which prompted us to investigate the effects of IL-1β gene silencing 
in chondrocytes cultured in an osteoarthritic model in vitro. 
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 Post-transcriptional silencing of IL-1β was achieved in chondrocytes cultured under 
monolayer conditions using a rAAV2 vector expressing a targeting short hairpin RNA 
sequence.   We chose to target IL-1β as it is the pivotal catabolic cytokine in damaged and/or 
inflamed cartilage.  IL-1β is upregulated in activated chondrocytes and is responsible for 
upregulation of ECM degrading enzymes including MMPs and aggrecanases, inhibition of 
proteoglycan and collagen type II production, and is involved in the IGF-I 
hyporesponsiveness seen in osteoarthritic chondrocytes.
1
  Effective IL-1β silencing following 
transduction with rAAV2-tdT-shIL-1β was confirmed by qPCR following stimulation of 
transduced chondrocytes with LPS.  Several important downstream effects of IL-1β silencing 
were also noted, including significant downregulation of TNF-α and ADAMTS-5, both of 
which play major roles in degradation of the ECM.  Additionally, we showed that IL-1β 
knockdown led to significantly decreased production of PGE2 by stimulated chondrocytes.  
PGE2 is a central inflammatory mediator involved in matrix degradation and the pain response 
associated with OA.
2
  Similar downstream effects were not observed in expression of 
ADAMTS-4, MMP-3, or MMP-13, all of which remained unchanged following IL-1β 
knockdown. 
 
 Although there were several beneficial effects of IL-1β silencing, persistent 
suppression of key matrix proteins, including collagen type II and aggrecan, seen in 
chondrocytes transduced with rAAV2-tdT-shIL-1β were of concern.  Additionally, increased 
expression of inflammatory mediators including RelA (p65) and IL-6 in transduced 
chondrocytes stimulated with LPS warrants further investigation, as these may be indicative 
of an intracellular immune response to AAV transduction, the presence of shRNA, or both.  
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Further experiments are required to evaluate the effect of AAV-mediated catabolic gene 
silencing in the equine chondrocyte to elucidate the intracellular response to this therapeutic 
approach.  In addition, the use of 3-dimensional chondrocyte cultures, such as pellet, 
micromass or alginate cultures, or cartilage explant cultures may be more useful systems to 
evaluate cartilage specific effects of IL-1β knockdown.  Due to the complex nature of RNA 
interference it is difficult to predict the in vivo effects of this technique using in vitro culture 
systems, thus an in vivo experiment may be required to fully investigate the benefits and 
drawbacks of IL-1β post-transcriptional silencing. 
 
The first two aims clearly demonstrated that rAAV is an effective vector for 
transducing articular cells and expressing both a larger peptide (IGF-I) and short hairpin 
sequence for RNA interference; however, understanding the immune response to AAV is key 
to its success as a clinically useful vector.  Innate and adaptive immune responses are capable 
of limiting vector effectiveness and transgene persistence, as well as creating significant 
safety concerns.   
 
The third aim in this dissertation research, which evaluated the local and systemic 
immune response to intra-articular injection of a rAAV2 and rAAV5 vector, demonstrated 
that there is a moderate humoral response to these vectors, especially AAV5, but a minimal T-
cell immune response in the horse.  We also demonstrated the existence of pre-existing NAbs 
to AAV5, and a more robust and diverse humoral response to this serotype, which did not 
appear to significantly impact growth factor formation.  Interestingly, all horses had pre-
existing NAbs to AAV5 while no horses had pre-existing NAbs to AAV2; however, rAAV5-
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IGF-I led to significantly higher levels of intra-articular IGF-I than rAAV2-IGF-I.  Overall, 
the presence of pre-existing NAbs in serum and synovial fluid and a more robust humoral 
response did not appear to limit vector effectiveness.  The lack of T-cell response observed in 
these horses, in comparison to humans, may be due to the route of administration (the joint is 
a relatively contained environment), use of low to moderate dose, or simply a difference in 
immune responses among species.  Although the horse is an excellent model for joint disease 
and cartilage repair, extrapolation of this data to humans is difficult as AAV immune 
responses are extremely variable between species.  Further investigations into the longevity of 
transgene expression and the effects of redosing joints with the same and alternative serotypes 
would be of great value.  This would allow evaluation of the usefulness of rAAV vectors as 
direct intra-articular therapy modalities that could be used to maintain sustained therapeutic 
protein levels in the joint.  The presence of pre-existing antibodies to AAV5 did not appear to 
limit transduction, as these joints had high levels of IGF-I; however, the significant increase 
in IgG1 and IgG4 observed following injection would likely limit transduction following 
redosing.  
 
In summary, this dissertation research showed that AAV-mediated gene therapy can 
improve the repair capability of implanted chondrocytes, and alter key catabolic cytokines and 
degradative enzymes of cartilage, by influencing both the anabolic and catabolic cascade.  
AAV was capable of articular cell transduction and transgene expression in vitro, ex vivo and 
in vivo.  Although AAV incited a humoral immune response following IA injection, a 
minimal inflammatory response in the joint and lack of a T-cell response are both 
encouraging findings.   
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 Future investigations into the impact of concurrent growth factor overexpression and 
catabolic cytokine knockdown is warranted as it is logical to assume that a synergistic effect 
will occur.  Together IGF-I and IL-1β are likely the two most important peptides in cartilage 
homeostasis with IGF-I promoting growth and repair, and IL-1β regulating degradation of the 
ECM.
3
  Gene therapy targeting both peptides is an attractive strategy for managing the injured 
or degenerative joint as this may more effectively restore cartilage homeostasis. The anabolic 
and catabolic cascades of chondrocytes are intimately linked, and control of both using a 
combinatorial gene therapy approach will likely offer superior treatment outcomes.   
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